

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

A

1677/97
JCS66
U.S. PTO

Patent Application of: Bianca M. Conti-Fine

METHODS TO TREAT UNDESIRABLE IMMUNE RESPONSES

Patent No.: 600.423US1

BOX PATENT APPLICATIONS

Assistant Commissioner for Patents
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A Utility Patent Application comprising:
 - ☒ Specification (95 pgs, including claims numbered 1 through 33 and a 1 page Abstract).
 - ☒ 11 Sheet(s) of Informal drawing(s).
 - ☒ An unsigned Combined Declaration and Power of Attorney (3 pgs).
- ☒ An Information Disclosure Statement (2 pgs.), Form 1449 (1 pgs.), and copies of 8 cited references.
- ☒ A return postcard
- Other: ____

The filing fee (NOT ENCLOSED) will be calculated as follows:

CLAIMS AS FILED					
	(1) No. Filed		(2) No. Extra	Rate	Fee
BASIC FEE	XXXXX		XXXXX	XXXXX	\$790.00
TOTAL CLAIMS	48 - 20	=	28	x 22 =	\$616.00
INDEPENDENT CLAIMS	11 - 3	=	8	x 82 =	\$656.00
[X] MULTIPLE DEPENDENT CLAIMS PRESENTED					\$270.00
TOTAL					\$2332.00

If the difference in Column (1) is less than zero, enter "0" in Column (2).

THE FILING FEE WILL BE PAID UPON RECEIPT OF THE NOTICE TO FILE MISSING PARTS.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)


By: 
Atty: Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EM014196877US

Date of Deposit: December 16, 1997

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, BOX PATENT APPLICATIONS, Washington, D.C. 20231.

By: 
Name: Patricia A. Hultman
(NEW FILING)

METHODS TO TREAT UNDESIRABLE IMMUNE RESPONSES

Statement of Government Rights

The present invention was made with the support of the United States
5 Government (National Institute of Neurological and Communicative Disorders and
Strokes, Grant NS 23919). The Government may have certain rights in the
invention.

Cross-Reference to Related Application

10 This application is a continuation-in-part of U.S. patent application Serial
No. 08/564,972, filed November 30, 1995, currently pending, which is incorporated
by reference herein.

Background of the Invention

15 Ideal treatments for a pathological condition or disease caused by an
undesirable immune response would specifically affect antigen-specific T and B
cells. Antigen specific tolerization of T cells can be obtained by delivery of the
antigen through routes, such as oral, intraperitoneal and nasal administration, that
downregulate, rather than activate, CD4+ responses (Matzinger, 1994; Nossal,
20 1995). Tolerization of T cells by those routes has proven effective for the
prevention and/or treatment of CD4+ T cell mediated autoimmune diseases, e.g.,
experimental autoimmune encephalomyelitis (EAE) (Metzler et al., 1993; Miller et
al., 1994; Genain et al., 1996; Al-Sabbagh et al., 1996), collagen-induced arthritis
(Al-Sabbagh et al., 1996), and experimental uveitis (Dick et al., 1993). Moreover,
25 the administration of the antigen by these methods reduced or inhibited the immune
response specific for the particular antigen administered. For example, aerosol
administration of myelin basic protein (MBP) to MBP-immunized rats that had
developed relapsing EAE decreased the intensity of the immune response to MBP
and the severity of the attacks (Al-Sabbagh et al., 1996). Spleen T cells from rats

that had inhaled MBP transferred protection to naive animals (Al-Sabbagh et al., 1996).

It is unclear whether similar approaches could be used for antibody (Ab)-mediated diseases for two reasons. First, while effective at reducing antigen-specific CD4+ responses, administration of antigen through routes that downregulate CD4+ responses may directly stimulate B cells specific for the administered antigen (Kuper et al., 1992; Liu et al., 1993; Husby et al., 1994; Neutra et al., 1996). This stimulation may have disastrous consequences, as has been shown in marmoset EAE (Genain et al., 1996), where intraperitoneal administration of myelin resulted in CD4+ tolerance to myelin, but also in an acute, fatal form of EAE. The fatal form of EAE was characterized by antibody specific for the myelin oligodendrocyte glycoprotein. Second, administration of antigen through routes that stimulate Th2 cells and downregulate pro-inflammatory Th1 cells can stimulate antibody synthesis (Neutra et al., 1996; Abbas et al., 1996), and cause exacerbation rather than improvement of antibody-mediated autoimmune diseases.

Short T epitope sequences may be safer for inducing T cell tolerance than the whole antigen molecule, since peptide-specific antibodies very seldom crossreact with the cognate native antigen (Conti-Fine et al., 1996). Peptides have been used with dubious success for oral tolerization in EAE (Karpus et al., 1996; Metzler et al., 1993), although peptides are not ideal for oral tolerization because they are easily digested by gastrointestinal proteases.

Thus, there is a need for an improved method to treat or inhibit antibody-mediated diseases.

Summary of the Invention

The present invention provides a therapeutic method comprising the administration of an "epitope" peptide comprising a universal and/or immunodominant epitope sequence derived from a particular antigen that is associated with an antibody-mediated disease in a mammal. The method

is effective to specifically tolerize, or down regulate the priming and/or activity of, the antigen-specific T cells of said mammal. The sequence of the epitope peptide does not include the entire sequence of the antigen from which it is derived.

Many autoimmune diseases and other pathological conditions are directly
5 caused by antibodies. Such antibodies are directed against proteins or other antigenic components of the host in diseases such as autoimmune diseases, or against exogenous substances in, for example, allergic diseases. The antibodies may also be directed against therapeutic agents, i.e., proteins or other antigenic substances given to the host for therapeutic purposes, such as the administration of
10 factor VIII to treat bleeding in hemophilia A patients. These therapeutic agents may be administered exogenously, or may be synthesized by the host as a result of gene therapy.

Antibody synthesis is controlled by T cells. In mammals there are limited sets of epitopes for each antigen that dominate the T cell response, referred to as
15 immunodominant T cell epitope sequences (hereinafter "immunodominant epitope sequences"). Moreover, in humans, CD4+ cells recognize universal, immunodominant epitope sequences. As T cell epitopes may comprise as few as 7 amino acid residues corresponding to an amino acid sequence present in a particular antigen, peptides having at least about 7 amino acid residues may be useful to
20 tolerize, or down regulate the priming and/or activity of, T cells (e.g., CD4+ cells) specific for the peptide and its corresponding antigen. Thus, immunodominant and/or universal epitope peptides may be administered so as to regulate a mammal's T cell and antibody response.

To determine whether the delivery of a given peptide is useful to inhibit or
25 treat a particular indication or disease in humans, the immunodominant and/or universal epitopes for a relevant antigen are identified. These epitopes are then identified, synthesized and administered to non-human mammals, preferably ones that are models for a particular human indication or disease, to determine whether the epitope peptide is useful to down regulate the T cell and antibody response to a

particular antigen. For example, rodents immunized with *Torpedo* fish AChR (TACHR) and, thus, susceptible to experimental myasthenia gravis (EMG) are useful to determine whether the administration of acetylcholine receptor (AChR)-derived epitope peptides can result in T cell tolerization. As described hereinbelow, EMG was induced in C57Bl/6 (B6) mice by immunization with purified TACHR. The immunized animals have sensitized CD4⁺ and B cells, and produce high affinity IgG antibodies which cross-react with mouse muscle AChR. The immunized B6 mice have anti-TACHR CD4⁺ T cells that recognize primarily epitopes within residues 146-169, 181-200 and 360-378 of the TACHR α subunit. Surprisingly, nasal administration of synthetic sequences of the TACHR α subunit representing epitopes recognized by anti-TACHR CD4⁺ T helper cells, given before and during immunization with TACHR, resulted in 1) decreased CD4⁺ responsiveness to those epitopes and to TACHR; 2) reduced synthesis of anti-TACHR antibodies; and 3) an absence of EMG.

Likewise, hemophilia A mice (factor VIII knockout mice), which do not produce factor VIII but produce anti-factor VIII antibodies after exogenous administration of factor VIII, are useful to test whether factor VIII T cell epitope peptides can down regulate the anti-factor VIII immune response in these mice.

With respect to universal, immunodominant CD4⁺ epitopes in humans, it has been shown that diphtheria toxin (DTX) and tetanus toxin (TTX) have such epitopes, see U.S. application Serial No. 08/564,972; Raju et al., 1995; Raju et al., 1996; Diethelm et al., 1997), respectively. As described hereinbelow, universal, immunodominant CD4⁺ epitope sequences exist on human AChR, the endogenous protein that is associated with the sensitization of CD4⁺ cells and production of high affinity IgG in myasthenia gravis (MG) patients. Moreover, the universal, immunodominant epitope sequences recognized by CD4⁺ T cells of MG patients can lead to the synthesis of pathogenic anti-AChR antibodies (Conti-Fine et al., 1997). Also as described hereinbelow, the majority of humans sensitized to factor VIII have CD4⁺ cells that recognize certain universal epitopes of factor VIII.

In particular, respiratory, e.g., nasal (upper) or lower respiratory tract, administration is a promising tolerizing route when using an epitope peptide, since the peptide does not need to overcome the proteolytic barriers present in the digestive system, and crosses the epithelia more readily than larger polypeptide molecules. Thus, synthetic CD4+ epitope sequences may be more effective than the whole or native antigen for tolerance induction. Moreover, the peptides of the invention can be prepared in large quantities and in high purity by chemical syntheses and thus are much less expensive and more readily obtained than a preparation comprising isolated autoantigen. Further, the delivery of epitope peptides to other mucosal surfaces, e.g., in the intestine, the mouth, the genital tract, and the eye, may also be employed in the practice of the methods of the invention, although the invention is not limited to administration by mucosal routes.

The administration of peptides to mucosal surfaces can result in a state of peripheral tolerance, a situation characterized by the fact that immune responses in non-mucosal tissues do not develop even if the peptide initially contacted with the mucosa is reintroduced, or its corresponding antigen is introduced or interacts with the immune system (e.g., in autoimmune diseases), in the organism by a non-mucosal route. Since this phenomenon is exquisitely specific for the peptide, and thus does not influence the development of systemic immune responses against other antigens, its use is particular envisioned for preventing and treating illnesses associated or resulting from the development of exaggerated immunological reactions against specific antigens encountered in nonmucosal tissues. For example, one embodiment of the invention is a method in which a mammal is contacted with a peptide of the invention via nasal inhalation in an amount that results in the T cells of said mammal having diminished capability to develop a systemic and/or peripheral immune response when they are subsequently contacted with an antigen comprising an immunodominant and/or universal portion of said peptide.

Thus, the invention provides a method of preventing or inhibiting an indication or disease associated with aberrant, e.g., excessive, pathogenic or

otherwise undesirable antibody production. The method comprises administering to a mammal afflicted with, or at risk of, the indication or disease an amount of a peptide, a variant thereof or a combination thereof, that is formally a fragment of a native antigen, and having an immunodominant and/or universal epitope sequence of said antigen which is effective to prevent or inhibit at least one symptom of the indication or disease. Preferably, for humans, the peptide comprises a universal, immunodominant epitope sequence. It is preferred that the peptide is administered to a mucosal surface. A preferred mucosal surface to which the peptides of the invention are administered is the respiratory tract.

- 10 Also provided is a method in which the administration of a peptide of the invention to a mammal results in the suppression, tolerization, or down regulation of the priming and/or activity, of T cells of a mammal at risk or, or having, an indication or disease associated with aberrant, pathogenic or otherwise undesirable antibody production. Further provided is a method in which the administration of a peptide of the invention results in the decrease in the amount or activity of antibodies which are characteristic of the particular disease or indication.
- 15 Preferably, the administration of a peptide of the invention to a mammal results in T cell tolerization, the down regulation of priming or activity of T cells, a reduction in the amount or affinity of pathogenic antibodies, the inhibition of at least one symptom of the indication or disease, or any combination thereof.
- 20

- The invention also provides a method to prevent or inhibit an indication or disease characterized by the presence of an antibody specific for an endogenous antigen. The method comprises administering to a mammal in need thereof an effective amount of a peptide, a variant thereof, or a combination thereof, wherein the peptide represents a fragment of said antigen and comprises an immunodominant and/or universal epitope sequence of said antigen. The administration is effective to reduce or eliminate at least one symptom of the indication or disease, tolerize or down regulate the priming or activity of T cells specific for the epitope and the antigen comprising said epitope, and/or decrease the
- 25

amount or affinity of the antibody for the endogenous antigen. Indications and diseases characterized by the presence of an antibody which binds an endogenous antigen include antibody-mediated autoimmune diseases such as myasthenia gravis, systemic lupus erythematosus, pemphigus, thrombic thrombocytopenic purpura and the like.

Preferably, the peptide is nasally administered to a human in an amount effective to suppress or tolerize, or down regulate the priming or activity of, the CD4+ cells of said human which induce the production of pathogenic antibodies. A preferred peptide to prevent or treat myasthenia gravis is a peptide that comprises a universal and/or immunodominant epitope sequence of human AChR. Likewise, preferred peptides that are useful to prevent or treat the undesirable immune responses to factor VIII that may develop in hemophilia A patients after treatment with factor VIII, or to factor IX that may develop in hemophilia B patients after treatment with factor IX, would be universal and/or immunodominant CD4+ epitope sequences of factor VIII and factor IX, respectively.

Yet another embodiment of the invention is a method to prevent or inhibit an indication or disease characterized by the presence of an antibody specific for an exogenous antigen, wherein the antigen is not associated with an infectious agent, e.g., a virus, bacteria or fungus, with the exception of viruses employed to transfer genes for gene therapy, and fungal components that cause allergic responses. The method comprises administering to a mammal in need thereof an amount of a peptide, a variant thereof, or a combination thereof, effective to reduce or eliminate at least one symptom of the indication or disease, tolerize or down regulate the priming or activity of, T cells specific for the epitope and/or decrease the amount or affinity of the antibody specific for the exogenous antigen. The administered peptide is a fragment of said antigen and comprises an immunodominant and/or universal epitope sequence of the exogenous antigen. For example, allergies are characterized by an exaggerated immune response to certain environmental factors. Thus, to prevent or inhibit an exaggerated antibody-mediated immune response to a

proteinaceous allergen, an effective amount of a peptide comprising an immunodominant and/or universal epitope sequence of the allergen, is administered to the mammal.

Further provided is a method to tolerize a mammal to an antigen associated with aberrant or pathogenic, or otherwise undesirable, antibody production in the mammal. The method comprises administering to the mammal an amount of at least one peptide, a variant thereof or a combination thereof, having a universal and/or immunodominant epitope sequence effective to tolerize, or down regulate the priming or activity of T cells of, the mammal to an antigen comprising said epitope, wherein said peptide is a fragment or subunit of said antigen.

Yet another embodiment of the invention is a method to identify an immunodominant epitope sequence in a mammal. The method comprises contacting at plurality of samples with a panel of peptides. Each sample comprises T cells and antigen presenting cells obtained from an individual mammal. The panel of peptides together correspond to the entire sequence of a particular antigen. Preferably, the peptides comprise overlapping sequences, i.e., each peptide comprises a sequence which overlaps with a portion of the sequence of at least one other peptide, such as the two adjacent peptides. Each sample is contacted with one of the peptides. Preferably, the mammals have been previously exposed to the antigen. Then it is determined whether the T cells from the mammal proliferate in response to one of the peptides relative to a sample contacted with an unrelated peptide that does not comprise an immunodominant epitope sequence and/or a sample which is not contacted with a peptide.

Another embodiment of the invention is a method to identify a universal epitope sequence useful to tolerize, or down regulate the priming or activity of, T cells of a mammal, e.g., a human. The method comprises contacting at least two samples with a preselected peptide, a variant thereof or combination thereof. One sample comprises T cells obtained from a first individual mammal. The second sample comprises T cells from a second mammal, wherein the genotype of the

second mammal differs at the immune response loci from the genotype of the first mammal, and wherein the mammals are of the same species. The samples to be tested preferably comprise T cells of a mammal that are sensitized to an antigen comprising said peptide. Preferably, the T cells are obtained from a mammal
5 having, or at risk of, an indication or disease associated with aberrant or pathogenic, or otherwise undesirable, antibodies to the antigen. Then it is determined whether or not the T cells from each mammal proliferate relative to (negative) control T cells which were not exposed to a peptide or any other antigenic stimulus, and/or relative to T cells exposed to a (negative) control peptide, i.e., one not having a universal
10 epitope sequence. A peptide having a universal epitope sequence will induce the proliferation of T cells from samples from a majority of mammals of the same species, mammals which differ at the immune response loci.

Thus, the invention also provides a tolerogen comprising at least one isolated and purified epitope peptide having a universal and/or immunodominant epitope
15 sequence and a physiologically compatible carrier, the administration of which to a sensitized mammal results in the suppression or reduction of the immune response of that mammal to an antigen which comprises at least an immunogenic portion of the peptide. Alternatively, the administration of at least one isolated and purified epitope peptide having a universal and/or immunodominant epitope sequence and a
20 physiologically compatible carrier, to a non-sensitized mammal results in the blocking of or a reduction in the priming to an antigen which comprises at least an immunogenic portion of the peptide, when such antigen is administered to the mammal in a manner that normally results in an immune response. It is preferred that the peptide contains a contiguous sequence of at least about 7 amino acids
25 having identity with the amino acid sequence of the antigen, and that the peptide is no more than about 40 amino acid residues in length, i.e., it represents a subunit of said antigen. It is also preferred that the tolerogen is nasally administered.

A further embodiment of the invention is a method to inhibit or suppress an antibody-mediated disease that is associated with the administration of an

endogenous protein or the use of gene therapy to replace such a protein. An endogenous protein that is administered so as to supplement or replace a deficiency in that protein includes, but is not limited to, insulin or fragments thereof, gamma globulins or fragments thereof, factor VIII or fragments thereof, factor IX or fragments thereof, cystic fibrosis transmembrane regulator or fragments thereof, growth hormone or fragments thereof, a transplantation antigen or fragments thereof and the like. Moreover, the endogenous protein may be recombinantly produced (referred to as "recombinant" protein or polypeptide). Replacement gene therapy includes the use of viral vectors to introduce and express a therapeutic gene, e.g., an endogenous protein. Because the endogenous protein or exogenous viral protein is "foreign" to the host, the host may have an immune response to these proteins. To suppress this response, a mammal at risk of, or having, a disease characterized by a decreased amount of, or a lack of, an endogenous protein or polypeptide, e.g., hemophilia A or B, adenosine deaminase deficiency, cystic fibrosis or diabetes, is administered a peptide, a variant thereof or a combination thereof in an amount effective to suppress or tolerize, or down regulate the priming and/or activity of, T cells specific for the endogenous protein. Similarly, to suppress an immune response to a viral protein present in a delivery vehicle for gene therapy, a mammal in need of gene therapy or subjected to gene therapy is administered a peptide, a variant thereof or a combination thereof in an amount effective to suppress or tolerize, or down regulate the priming and/or activity of, T cells specific for the viral protein. Preferably, the epitope peptide is a subunit of the endogenous protein and comprises immunodominant and/or universal epitope sequences derived from the endogenous protein, e.g., peptides of factor VIII for hemophilia A, or an epitope peptide derived from the viral protein of the viral vector employed for gene therapy, e.g., peptides of a retrovirus or adenovirus glycoprotein or capsid protein.

Also provided is a therapeutic method, comprising: nasally administering to a mammal subjected to gene therapy which employs a recombinant virus as a delivery vehicle, an amount of an epitope peptide, a variant thereof or a combination

thereof effective to suppress an immune response to the virus-specific proteins present in the delivery vehicle, wherein the peptide comprises an immunodominant and/or universal epitope sequence of the virus protein.

Further provided is therapeutic method, comprising: nasally administering to
5 a mammal having an indication or disease characterized by a decreased amount or a lack of an endogenous protein, wherein the mammal is subjected to exogenous introduction of the protein or the corresponding recombinant polypeptide, an amount of an epitope peptide, a variant thereof or a combination thereof effective to suppress an immune response to the exogenously introduced protein or polypeptide,
10 wherein the indication or disease is associated with aberrant or pathogenic antibody production to the endogenous protein, and wherein the epitope peptide is a subunit of the endogenous protein and comprises an immunodominant and/or universal epitope sequence of the endogenous protein.

Also provided is a method to treat an antibody-mediated disease in a
15 mammal wherein the disease is characterized by antibodies specific for an antigen. The method comprises administering to the mammal a dosage form comprising an amount of at least one epitope peptide, a variant thereof or a combination thereof, effective to prevent or inhibit at least one symptom of said disease, suppress or tolerize, or down regulate the priming and/or activity of, T cells specific for the
20 antigen, and/or inhibit or decrease the amount or activity of the antibody which is specific for the antigen. The peptide is a fragment of the antigen and comprises an immunodominant and/or universal epitope sequence of the antigen comprises the immunodominant and/or universal epitope sequence. The mammal is also subjected to plasmapheresis either before, during or after, or any combination thereof, peptide
25 administration so as to decrease the amount of circulating antibodies which include the antibodies specific for the antigen. Optionally, an immunosuppressive agent may also be administered so as to decrease B cell activation.

Brief Description of the Figures

Figure 1. Nasal administration of synthetic TACHR epitopes T α 150-169, T α 181-200 and T α 360-378 causes T cell unresponsiveness to those epitopes. Mice were given two nasal administrations of peptide T α 150-169 (panel A, dotted columns), or α pool (panel B, white columns), or peptide-free PBS (black columns) prior to immunization with the peptide(s) used for the nasal treatment. Seven-ten days after the last immunization, the proliferative response of spleen T cells to the immunizing peptide(s) and to TACHR was tested. The data depicted are the results obtained for one mouse from each group, which is representative of the results obtained for all mice of that group. The response induced by 10 μ g of PHA is also shown. The columns represent the average S.I. of triplicate cultures. The average c.p.m. obtained in the absence of any stimulation were 297 \pm 59 in experiment A and 2,884 \pm 106 in experiment B.

Figure 2. Nasal administration of synthetic TACHR CD4+ epitope peptides inhibits EMG. Peptide T α 150-169, α pool or peptide-free PBS was administered nasally twice prior to immunization with TACHR, and at different time intervals during the course of the immunization (monthly, panel A; weekly, panel B). Three immunizations with 50 μ g of TACHR, one month apart, were also administered. The data depict the muscle strength of the mice after the third TACHR injection. Muscle strength is measured as holding time using the curare sensitized hanging test described hereinbelow (see Example I). "Normal" mice were mice having a holding time of eight minutes or more; moderately sick mice were those with holding times between four and eight minutes; and severely sick mice were those with holding times of less than four minutes. The four and eight minute levels are indicated by dashed horizontal lines. The panel marked "naive" depicts the values obtained for the mice prior to immunization with TACHR. The other plots depict the results obtained for mice sham-tolerized with PBS or mice tolerized with peptide T α 150-169 or with α pool, as indicated above the plots. The average holding time \pm S.D. of the

different groups is indicated, as is the level of significance of the difference compared to the sham-tolerized group (** $P < 0.002$; * $P < 0.02$).

Figure 3. Spleen T cells from mice treated nasally with synthetic TACHR T epitope sequences and immunized with TACHR respond minimally to peptide α 150-169 and respond to the TACHR to a lesser extent than the T cells from sham-tolerized controls. Mice received weekly nasal administrations of peptide-free PBS (circles), T α 150-169 (squares) or α pool (triangles) as indicated below of each plots, and were immunized three times with TACHR. The spleen T cells of individual mice were tested in proliferation assays with TACHR or individual peptides, i.e., T α 150-169, T α 181-200 or T α 360-378. The data are the average S.I. \pm S.D. of triplicate cultures. The c.p.m. in the absence of any stimulation were 190 ± 88 . The proliferative responses of mice that had EMG are indicated with black symbols. The average responses of the different groups, and the level of significance of the difference between peptide-tolerized and sham-tolerized mice, are shown (** $P < 0.01$; * $P < 0.03$).

Figure 4. Mice treated nasally with TACHR peptides have less serum anti-TACHR antibodies than sham-tolerized mice. The concentration of anti-TACHR antibodies in the sera of individual mice was determined at 4, 8 and 10 weeks after the first TACHR immunization. Mice were tolerized by weekly inhalations (protocol B) of peptide T α 150-169 (squares), α peptide pool (triangles) or sham-tolerized with peptide-free PBS (circles), and immunized three times with TACHR, as indicated above the plots. The antibody concentration is expressed as μ M precipitated 125 I- α -bungarotoxin (BTX) binding sites. Mice that presented EMG symptoms are indicated by black symbols. The average antibody concentrations of the different groups and the level of significance of the difference between peptide-tolerized and sham-tolerized mice are indicated.

Figure 5. Nasal administration of synthetic DTX peptides does not affect the development of EMG or the anti-AChR T cell response. A) Muscle strength of individual mice. Mice were treated nasally with α pool or DTX peptides and their

muscle strength measured after the third TACHR injection as described in the legend to Figure 2. The 4- and 8- minute levels are indicated by dashed horizontal lines.

B) Proliferative response to TACHR (5 and 10 μ g, as indicated) of triplicate cultures of pooled spleen T cells of four mice from each group, after the third TACHR immunization (white columns, α -pool treated mice; black columns, DTX peptide treated mice). The columns represent average S.I. \pm S.D. of triplicate cultures. The c.p.m. in the absence of any stimulation were 228 \pm 29 for the DTX peptide-tolerized mice, and 190 \pm 17 for the α -pool tolerized mice.

Figure 6. The reduction of the *in vitro* response to TACHR of spleen T cells from AChR peptide-tolerized mice is reversed by IL-2 treatment. After the third TACHR injection, spleen T cells of mice sham-tolerized or tolerized with the α pool were pooled, incubated with (black columns) or without (white columns) IL-2, and tested in a proliferation assay for their response to TACHR. The columns represent average S.I. \pm S.D. of sextuplicate cultures. The c.p.m. in the absence of any stimulation were 410 \pm 124 for the sham-tolerized mice, and 366 \pm 78 for the (α pool-tolerized mice). The star indicates a significant difference of the proliferative response of cells treated with IL-2, as compared with the non treated cells (P<0.0001).

Figure 7. Nasal treatment with AChR peptides stimulates AChR specific Th2 cells. Secretion of IL-2 and IL-10 in response to challenge with TACHR (10 μ g) by pooled spleen T cells of 4 mice treated nasally (protocol B) with PBS (white columns) or a pool (black columns), after three TACHR injections. Controls were cultures that did not receive any stimulus. The columns represent the average (n=6) of the data obtained 24 hours after TACHR addition to the culture for IL-2, 48 hours for IL-10. The data are expressed as O.D. units detected in ELISA.

Figure 8. The proliferative response to the TACHR of spleen T cells from TACHR immunized mice is not affected by the presence in the culture of peptide specific immunoregulatory Th2 cells. Spleen T cells from mice treated nasally with DTX peptides and immunized three times with TACHR were tested in a proliferative

assay with TACHR, with the DTX peptide pool (2.5 and 5 µg of each peptide), and with both TACHR and DTX peptides. The bar is the average S.I. of triplicate cultures. The c.p.m. in the absence of any stimulation were 149±97.

Figure 9. Codons for specified amino acids.

5 Figure 10. Exemplary and preferred amino acid substitutions for variant peptides or polypeptides of the invention.

Figure 11. Response of human T cells to factor VIII peptides.

Detailed Description of the Invention

10 **Definitions**

“Immunodominant” CD4⁺ cell epitopes (also referred to as immunodominant T cell epitopes or immunodominant epitope sequences) refer to a sequence of a protein antigen, or the proteinaceous portion of an antigen, that is strongly recognized by the CD4⁺ cells of a mammal sensitized to that antigen, as
15 detected by methods well known to the art, including methods described herein. “Strongly” recognized means that the peptide elicits a statistically significant response as compared to the background response to a non-related peptide from an antigen to which the mammal is not sensitized, and that such response is at least two times higher than the average response obtained for at least about 1/3 of the peptides
20 which elicit the lowest response from the peptides employed to identify the immunodominant epitopes.

T cell epitopes can vary in size, and as few as 7 consecutive amino acid residues of a particular antigen may be recognized by CD4⁺ cells. Thus, an immunodominant epitope sequence is an amino acid sequence containing the
25 smallest number of contiguous amino acid residues which are strongly recognized by T cells from an individual mammal. An epitope peptide of the invention may comprise more than one immunodominant epitope sequence, and may comprise sequences which do not contain an immunodominant epitope sequence. Sequences which do not contribute to an immunodominant epitope sequence can be present at

either or both the amino- or carboxyl-terminal end of the peptide. The non-immunodominant epitope sequences preferably are no more than about 10-20 peptidyl residues *in toto*, and either do not affect the biological activity of the peptide or do not reduce the activity of the peptide by more than 10-20%.

- 5 Preferably, epitope peptides having immunodominant epitope sequences are useful to tolerize, or down regulate the priming and/or activity of T cells of, a mammal to an antigen having said sequences so as to result in a reduction in the amount or activity of antibodies to said antigen in said mammal.

As used herein, a "universal" epitope sequence is an epitope that is
10 recognized by CD4+ cells from a majority, preferably at least about 66%, more preferably at least about 75%, of individuals within a population of a particular mammalian species that is genetically divergent at the immune response loci, e.g., at the HLA loci in humans. T cell epitopes can vary in size, and as few as 7
15 consecutive amino acid residues of a particular antigen may be recognized by CD4+ cells. Thus, within the scope of the invention, a universal epitope comprises an amino acid sequence containing the smallest number of contiguous amino acid residues which are recognized by CD4+ cells from a majority of mammals from the same species which are genetically different at their immune response loci. A peptide of the invention may comprise more than one universal epitope sequence,
20 and may comprise sequences which do not contain a universal epitope sequence. Preferably, at least a majority, i.e., 51%, of the amino acid sequence of the peptide comprises a universal epitope sequence. Sequences which do not contribute to a universal epitope sequence can be present at either or both the amino- or carboxyl-terminal end of the peptide. The non-universal epitope sequences preferably are no
25 more than about 10-20 peptidyl residues *in toto*, and either do not affect the biological activity of the peptide or do not reduce the activity of the peptide by more than 10-20%.

The term "tolerance" is here defined as a reduction in the T cell and/or antibody response which is specific for a given antigen. The reduction in the

antibody response may be concomitant with increased sensitization and/or response of special subsets of T cells specific for the antigen, for example CD4+ Th2 cells which have immunoregulatory functions.

As used herein, the terms “isolated and/or purified” refer to *in vitro* preparation, isolation and/or purification of a peptide or nucleic acid molecule of the invention, so that it is not associated with *in vivo* substances, or is substantially purified from *in vitro* substances.

As used herein, the term “immunogenic” with respect to a peptide of the invention means that the peptide can induce non-tolerized peripheral blood mononuclear cells (PBMC) or other lymphoid cells from a sensitized mammal to proliferate or secrete cytokines when those cells are exposed to the peptide relative to cells not exposed to the peptide, and/or that the administration of the peptide to a mammal causes an immune response to the peptide.

A “sensitized” mammal is a mammal that has been exposed to a particular antigen, as evidenced by the presence of antibodies or T cells specific to the antigen. Preferably, the mammal has high affinity, e.g., IgG, antibodies to the antigen. A sensitized mammal within the scope of the invention includes mammals having or at risk of an antibody-mediated indication or disease as defined herein.

As used herein, an “exogenous” antigen does not include antigens of an infectious agent, e.g., a virus, bacteria or fungus, with the exception of viruses employed to transfer genes for gene therapy, and fungal components that cause allergic responses.

As used herein, an “endogenous” antigen includes proteins that are normally encoded by the genome of and expressed in a mammal.

As used herein, the term “aerosol” includes finely divided solid or liquid particles that may be created using a pressurized system such as a nebulizer or instilled into a host. The liquid or solid source material contains a peptide or a nucleic acid molecule of the invention, or a combination thereof.

An "epitope" peptide of the invention is a peptide subunit that comprises at least about 7 and no more than 40 amino acid residues which have 100% contiguous amino acid sequence homology or identity to the amino acid sequence of a particular antigen, e.g., human AChR or factor VIII. An epitope peptide of the invention comprises a universal and/or immunodominant epitope sequence. The administration of an epitope peptide of the invention to a sensitized mammal results in a mammal that is tolerized to the antigen from which the epitope peptide is derived. Preferably, the administration of an epitope peptide of the invention to a mammal does not result in the stimulation of B cells specific for the peptide.

As employed herein, a "variant" of an epitope peptide of the invention refers to a peptide which comprises at least about 7 and no more than about 40, peptidyl residues which have at least about 70%, preferably about 80%, and more preferably about 90%, but less than 100%, contiguous homology or identity to the amino acid sequence of a particular antigen. A variant peptide of the invention comprises a universal and/or immunodominant epitope sequence. The administration of a variant peptide of the invention to a sensitized mammal results in a mammal that is tolerized to the peptide, and to the antigen from which the peptide is derived. Preferred variant peptides of the invention do not reduce the biological activity of the peptide by more than 10-20% relative to the corresponding non-variant peptide.

As used herein, the term "biological activity" with respect to a peptide of the invention is defined to mean that the administration of the peptide, preferably via a mucosal surface such as the respiratory tract, to a mammal results in the mammal developing tolerance to an antigen having at least a portion of the peptide administered.

"Replacement gene therapy" as used herein means therapy intended to supplement reduced amounts or the complete absence of an endogenous protein. The therapy may include the administration of isolated native protein or recombinant polypeptide to the mammal in need thereof, or the administration of a recombinant viral vector encoding said polypeptide.

An "indication or disease" within the scope of the invention includes antibody-mediated diseases as well as cell-mediated diseases. Antibody-mediated diseases include, but are not limited to, autoimmune diseases such as myasthenia gravis, and allergic diseases such as those described below. Antibody-mediated indications within the scope of the invention include, but are not limited to, indications characterized by undesirable antibody responses to substances administered for therapeutic purposes such as antibody responses to endogenous proteins that are exogenously administered, and to viral proteins or the protein encoded by a viral vector that is employed for gene therapy.

10

I. The Immune Response

The capacity to respond to immunologic stimuli resides primarily in the cells of the lymphoid system. During embryonic life, a stem cell develops, which differentiates along several different lines. For example, the stem cell may turn into a lymphoid stem cell which may differentiate to form at least two distinct lymphoid populations. One population, called T lymphocytes, is the effector agent in cell-mediated immunity, while the other, called B lymphocytes, is the primary effector of antibody-mediated, or humoral, immunity. The stimulus for B cell antibody production is the attachment of an antigen to B cell surface immunoglobulin. Thus, B cell populations are largely responsible for specific antibody production in the host. For most antigens, B cells require the cooperation of antigen-specific T helper (CD4+) cells for effective production of high affinity antibodies.

Of the classes of T lymphocytes, T helper (Th) or CD4+ cells, are antigen-specific cells that are involved in primary immune recognition and host defense reactions against bacterial, viral, fungi and other antigens. CD4+ cells are necessary to trigger high affinity IgG production from B cells for the vast majority of antigens. The T cytotoxic (Tc) cells are antigen-specific effector cells which can kill target cells following their infection by pathologic agents.

While CD4⁺ cells are antigen-specific, they cannot recognize free antigen. For recognition and subsequent CD4⁺ activation and proliferation to occur, the antigen must be processed by suitable cells (antigen presenting cells, APC). APC fragment the antigen molecule and associate the fragments with major

5 histocompatibility complex (MHC) class II products (in humans) present on the APC cell surface. These antigen fragments, or T cell epitopes, are thus presented to receptors or a receptor complex on the CD4⁺ cell in association with MHC class II products. Thus, CD4⁺ cell recognition of a pathogenic antigen is MHC class II restricted in that a given population of CD4⁺ cells must be either autologous or

10 share one or more MHC class II products with the APC. Likewise, Tc cells recognize antigen in association with MHC class I products.

In the case of CD4⁺ cells, this antigen presenting function is performed by a limited number of APC. It is now well established that CD4⁺ cells recognize peptides derived from processed soluble antigen in association with class II MHC

15 product, expressed on the surface of macrophages. Recently, other cell types such as resting and activated B cells, dendritic cells, epidermal Langerhans' cells, and human dermal fibroblasts have also been shown to present antigen to CD4⁺ T cells.

If a given CD4⁺ cell possesses receptors or a receptor complex which enable it to recognize a given MHC class II product-antigen complex, it becomes activated,

20 proliferates and generates lymphokines, such as interleukin 2 (IL-2). The lymphokines in turn cause the proliferation of several types of "killer" cells, including Tc cells and macrophages, which can exhibit antimicrobial and tumoricidal activity.

After stimulation subsides, survivors of the expanded CD4⁺ cells remain as

25 member cells in the body, and can expand rapidly again when the same antigen is presented.

Numerous attempts have been made to isolate and maintain homogenous populations of Tc or CD4⁺ cells and to characterize them in terms of their antigen specificity and MHC restriction. These attempts usually involve the stimulation of

mononuclear cells from a seropositive human or murine host with antigenic bacterial or viral preparations in combination with nonproliferative APC, such as irradiated autologous mononuclear cells (MNC). Proliferating polyclonal populations of CD4⁺ cells or Tc cells can be cloned by limiting dilution to obtain
5 homogenous populations and then further proliferated and characterized by a variety of techniques.

Methods of determining whether PBMCs or lymphoid cells have proliferated, or produced or secreted interleukins, are well known in the art. For example, see Paul, Fundamental Immunology, 3rd ed., Raven Press (1993), and
10 Benjamini et al. (eds.), Immunology: A Short Course, John Wiley & Sons, Inc., 3rd ed. (1996).

II. Indications Amenable to Treatment by the Peptides of the Invention, or Nucleic Acid Molecules Encoding the Peptides

15 The peptides or nucleic acid molecules of the invention are useful to treat a mammal afflicted with, or to inhibit in a mammal at risk of, an indication or a disease characterized by aberrant or pathological, or undesirable, antibody production which is specific for a particular antigen, e.g., an antibody-mediated autoimmune disease. Preferably, these efficacious peptides are recognized by CD4⁺
20 cells from a majority of mammals having or at risk of the indication or disease, and, more preferably, these epitopes are recognized by CD4⁺ cells that induce the synthesis of pathogenic antibody and/or excessive amounts of the antibody. Indications or diseases associated with aberrant, pathological or undesirable antibody production include, but are not limited to, autoimmune disease
25 (endogenous antigen), replacement gene therapy (endogenous and/or exogenous antigen), proteins administered for therapeutic purposes (endogenous and/or exogenous antigen) or allergies (exogenous antigen). Thus, a peptide may be selected so as to inhibit or treat an indication or disease characterized by aberrant, pathological or undesirable antibody production which is antigen specific, thereby

minimizing side effects resulting from disrupting unrelated physiological processes or side effects associated with administration of full-length antigen.

A. Autoimmune Diseases

5 Autoimmune diseases are characterized by an abnormal immune response involving either cells or antibodies, that are in either case directed against normal autologous tissues. Autoimmune diseases in mammals can generally be classified in one of two different categories: cell-mediated disease (i.e., T-cell) or antibody-mediated disorders. Non-limiting examples of cell-mediated autoimmune diseases
10 include multiple sclerosis, rheumatoid arthritis, Hashimoto thyroiditis, type I diabetes mellitus (Juvenile onset diabetes) and autoimmune uveoretinitis (see Table 1). Antibody-mediated autoimmune disorders include, but are not limited to, myasthenia gravis, systemic lupus erythematosus (or SLE), Graves' disease, autoimmune hemolytic anemia, autoimmune thrombocytopenia, autoimmune
15 asthma, cryoglobulinemia, thrombic thrombocytopenic purpura, primary biliary sclerosis and pernicious anemia (see Table 1). The antigen(s) associated with systemic lupus erythematosus is small nuclear ribonucleic acid proteins (Snurps), Graves' disease is the thyrotropin receptor, thyroglobulin and other components of thyroid epithelial cells (Akamizu et al., 1996; Kellerman et al., 1995; Raju et al.,
20 1997; and Texier et al., 1992), pemphigus is cadherin-like pemphigus antigens such as desmoglein 3 and other adhesion molecules (Memar et al., 1996; Stanley, 1995; Plott et al., 1994; and Hashimoto, 1993), and thrombic thrombocytopenic purpura is antigens of platelets.

Other autoimmune diseases and their specific autoantigens and/or target
25 tissues are disclosed in Schwartz, R. S. et al. in Fundamental Immunology, Third Edition, Paul, W. E., Ed., Raven Press, New York, 1993, which is incorporated by reference herein.

The current treatments for both categories of autoimmune diseases involve administration of drugs which non-specifically suppress the immune response.

Examples of such drugs are methotrexate, cyclophosphamide, Imuran (azathioprine) and cyclosporin A. Steroid compounds such as prednisone and methylprednisolone are also employed in many instances. These drugs have limited efficacy against both cell- and antibody-mediated autoimmune diseases. Use of such drugs is

5 limited by virtue of their toxic side effects and also because they induce “global” immunosuppression in a patient receiving prolonged treatment with the drug, e.g., the normal protective immune response to pathogenic microorganisms is downregulated thereby increasing the risk of infections caused by these pathogens. A further drawback is that there is an increased risk that malignancies developing in

10 patients receiving prolonged global immunosuppression.

TABLE 1

	Disease Model	Specific Autoantigen
15	Multiple Sclerosis	MBP
	Rheumatoid Arthritis	Collagen
	Autoimmune Thyroiditis	Thyroglobulin
	Myasthenia Gravis	Acetylcholine receptor
	Autoimmune uveoretinitis	S-antigen
20	Systemic Lupus Erythematosus	DNA
	Diabetes	islet cell extract
	Chronic Active Hepatitis	Liver extract
	Adrenalitis	Adrenal gland extract
	Polymyositis	Muscle extract
25	Autoimmune hemolytic anemia	Hematopoietic cells
	Rheumatic carditis	Heart extract
	Scleroderma	Skin cell extract

An autoimmune disease is a malfunction of the immune system of mammals,

30 including humans. In a mammal afflicted with such a disease, the immune system treats autologous tissues (self or endogenous antigens) and substances as if they were foreign and dangerous, and evokes the immune defense that is usually reserved

for use against exogenous and dangerous substances (e.g., foreign tissues or invading organisms), including sensitization of T cells and synthesis of high affinity antibodies.

5 B. Replacement Therapies which employ Protein Therapeutics or Gene Therapy

The identification of underlying genetic defects has made gene therapy an attractive treatment option for a wide variety of diseases. Gene therapy is particularly useful in indications or diseases that result from a defect in a single gene. A deficiency in an endogenous protein in a mammal may occur neonatally or
10 later in the mammal's life. The deficiency may be a complete lack of the endogenous protein, e.g., due to a genetic defect in the gene encoding the protein, or a reduced amount of an endogenous protein relative to a majority of other mammals of the same species. In either case, the deficiency may be enough to result in a particular disorder or disease. For example, a deficiency in factor VIII causes
15 hemophilia A and a deficiency in factor IX causes hemophilia B. To supplement these deficiencies, certain proteins can be administered to the mammal so as to treat or prevent the disease. A different approach to treat or prevent genetic defects which result in disease is to introduce a "normal" gene that encodes the endogenous protein to the mammal having the deficiency. Viral vectors are one method which
20 has been employed to introduce particular genes into mammals. However, the introduction of endogenous proteins, their recombinantly produced counterpart polypeptides, or recombinant viruses having genomes that encode the endogenous protein can result in an immune response to the foreign proteins, the endogenous protein, the recombinant polypeptide, or the viral capsid or glycoproteins.

25 Thus, therapies in which an endogenous protein is administered to treat a particular disease can result in an antibody mediated response which is specific for that protein. One example of such a disease is hemophilia. For example, certain hemophiliacs lack or have reduced amounts of factor VIII. These patients are treated with isolated native factor VIII or recombinant factor VIII. However, some

of these patients develop antibodies to factor VIII that block or inhibit factor VIII activity that reduces the efficacy and increases the cost of the therapy. Likewise, an immune reaction to a native or recombinant protein that is introduced into a mammal to supplement a deficiency in that protein may be prevented or treated by the compounds, compositions and methods of the invention. Such proteins include, but are not limited to factor IX, growth hormone, adenine deamidase (ADA), β -globin, HPRT, purine nucleoside phosphorylase, α 1-anti-trypsin, glucocerebrosidase, argininosuccinate synthase, phenylalanine hydroxylase, low density lipoprotein receptor, interleukins, cytokines, dystrophin, ciliary neurotrophic factor (for ALS), fibrosis transmembrane conductance regulator (for cystic fibrosis), p47, alpha-L-hyaluronidase (Hurler syndrome), prolidase, N-acetylgalactosamine (mucopolysaccharidosis type VI), β -glucuronidase (mucopolysaccharidosis type VII), ornithine transcarbamylase, liver arginine ureahydrolase, or insulin, may result in the mammal developing antibodies to the administered protein. The methods of the invention are particularly useful to prevent or treat such indications or diseases by tolerizing, or down regulating the priming and/or activity of the T cells of, mammals having such indications or diseases with a peptide having a universal and/or immunodominant epitope sequence from the protein antigen employed for therapeutic purposes.

Successful gene therapy requires the identification of an appropriate therapeutic gene for treatment of the disease, but may also require a delivery system by which that gene can be introduced to the recipient or to a desired cell type both efficiently and accurately. One such delivery system currently employed in clinical trials employs a viral vector to deliver the desired gene to the host organism. The expression of the gene results in the synthesis of the encoded protein in an amount which supplements the amount present in the mammal prior to therapy, preferably so as to inhibit or reduce at least one symptom of the disease.

Viral vectors that have been approved for gene therapy clinical trials include retroviral vectors, adenovirus vectors and adeno-associated virus vectors (see

Marshall, Science, 269, 1050-1059 (1995)). The introduction of viral vectors and the expression of an endogenous gene product that is not expressed or poorly expressed is that the immune response to the vector-encoded viral proteins (exogenous) results in sensitization of the recipient to those antigens. Thus, the beneficial effects of gene therapy are reduced as a result of the patient's immune system recognizing the viral proteins, as well as the expressed endogenous gene product, as "foreign".

C. Exogenous Antigens

Allergic diseases within the scope of the invention include allergic rhinitis, allergic asthma, atopic dermatitis, allergic gastroenteropathy, anaphylaxis, urticaria and angioedema. Allergens within the scope of the invention include, but are not limited to, protein antigens of *Alternaria alternata* (Alt a I), *Artemisia vulgaris* (Art v II), *Aspergillus fumigatus* (Asp f II), *Dermatophagoides far.* (Der f I), *Dermatophagoides pteron.* (Der p I, Der p III, Der p IV, Der p VI and Der p VIII), and domestic animals such as *Felis domesticus* (Fel d I), cows, pigs, poultry, mice, hamsters, rabbits, rats, guinea pigs, dogs and horses. Common fungal antigens include those of Basidiomycetes such as *Ustilago*, *Ganoderma*, *Alternaria*, *Cladosporium*, *Aspergillus*, *Sporobolomyces*, *Penicillium*, *Epicoccum*, *Fusarium*, *Phoma*, *Borerytis*, *Helminthosporium*, *Stemphylium* and *Cephalosporium*; Phycomycetes such as *Mucor* and *Rhizopus*; and Ascomycetes such as *Eurotium* and *Chaetomium*.

Pollinating plants which may have protein antigens associated with allergies include club mosses, ferns, conifers, flowering plants, grasses, sedges, palms, cattails, nettles, beeches, chenopods, sorrels, willows, poplars, maples, ashes, ragweeds (antigen E, antigen K and Ra3) and sages, or proteinaceous plant products such as those found in latex products.

Hymenoptera insects that may have protein antigens associated with allergies include the honeybee, yellow jacket, hornet, wasp and fire ant, although protein antigens of other insects are also within the scope of the invention.

Allergies associated with foods may be the result of protein antigens in
5 crustaceans (e.g., shrimp, lobster and crab), mollusks (e.g., clams), fish, legumes (e.g., peanut, pea, beans, and licorice), seeds (e.g., sesame, cottonseed, caraway, mustard, flaxseed, and sunflower), nuts, berries, egg white, buckwheat and milk.

III. Identification of an Epitope Peptide Falling within the Scope of the Invention

10 The identification of a universal and/or immunodominant epitope sequence in an antigen permits the development and use of a peptide-based tolerogen to the antigen. The administration of epitope peptides which contain a universal and/or immunodominant epitope sequence can induce a tolerizing effect in many, if not all, mammals, preferably those of differing immune response haplotypes. Moreover,
15 the use of peptide tolerogens is less likely to produce the undesirable side effects associated with the use of the full-length antigen. These epitope peptides can be identified by *in vitro* and *in vivo* assays, such as the assays described hereinbelow (see, for example, Conti-Fine et al., 1997; and Wang et al., 1997). It is recognized that not all agents falling within the scope of the invention can result in tolerization,
20 or result in the same degree of tolerization.

To identify epitope peptides useful to tolerize a mammal having or at risk of an indication or disease within the scope of the invention, the antigen which is associated with the indication or disease is identified. The antigen may be an endogenous antigen, e.g., the AChR, or an exogenous antigen, e.g., a viral
25 glycoprotein or an endogenous antigen, such as factor VIII, administered exogenously to correct a deficiency in that protein. The amino acid sequence of that antigen is then obtained or determined. Generally, 20 residue peptides are obtained or prepared which span the entire amino acid sequence of the antigen and which overlap the adjacent peptide by 5-10 residues, see U.S. application Serial

No.08/564,972. In this manner, a peptide may include sequences which correspond to a portion of a universal and/or immunodominant epitope sequence. These peptides are then individually screened *in vitro* and *in vivo*.

- In vitro* methods useful to determine whether a particular peptide comprises
- 5 a universal and/or immunodominant epitope sequence include determining the biological activity (e.g., inducing the proliferation of or cytokine secretion by T cells) of the peptide in CD4+ cell lines that are specific for an antigen having the peptide, isolated CD4+ cells, CD8+ depleted spleen or lymph node cells, or CD8+ depleted peripheral blood mononuclear cells (PBMC). These cells may be obtained
- 10 from a mammal at risk or of having an indication or disease within the scope of the invention or from a mammal that is "normal". In either case, the mammal is preferably known to be sensitized to the antigen. Epitope peptides useful in the practice of the invention include a peptide that is strongly recognized by the T cells of the mammal tested, i.e., they have an immunodominant epitope sequence.
- 15 Preferred epitope peptides are those which are recognized by the T cells of at least a majority of mammals having divergent immune response haplotypes, e.g., MHC class II molecules in humans. This recognition can be measured by the ability of the peptide to induce proliferation or cytokine secretion in T cells obtained from mammals with known or suspected divergent haplotypes and/or by direct HLA class
- 20 II binding assays (Manfredi et al., 1994; Yuen et al., 1996).

- Thus, CD8+ depleted PBMC, CD8+ depleted spleen or lymph node cells or CD4+ lines specific for an antigen or epitope can be contacted with an epitope peptide and the proliferation of the cells measured or the amount and type of cytokine secreted detected. Th1 cytokines include IFN- γ , IL-12 and IL-2. Th2
- 25 cytokines include IL-4 and IL-10. An immunospot ELISA or other biological assay is employed to determine the cytokine which is secreted after the peptide is added to the culture.

Epitope peptides falling within the scope of the invention may also be identified by *in vivo* assays, such as animal models for a particular indication or

disease. Generally, the animal is contacted with a particular peptide, or a plurality of peptides, preferably ones which were identified as having immunodominant epitope sequences. The animal is then immunized with an antigen having sequences corresponding to at least a portion, i.e., the immunodominant epitope sequence, of the peptide. The tolerogenic efficacy of the peptide is then determined. For example, T cells may be isolated from these animals and their response to antigen or peptide *in vitro* measured, or the amount of antibody specific for the antigen obtained at time periods before immunization and after immunization compared. Also, the reduction or inhibition of specific phenotypic indicators of disease, e.g., muscle response in animals having EMG, may be used to determine the tolerogenic effect of the peptide.

One animal model is described in Example I (EMG). Another model is described in Example II. Example II describes how Factor VIII sequences having immunodominant epitope sequences are identified using CD4⁺ spleen and lymph node cells of hemophilia A mice. Then the identified epitope peptides can be administered to naive hemophilia A mice, preferably by nasal administration, followed by immunization with factor VIII. The efficacy of the tolerizing treatment is then determined by methods similar to those described in Example 1.

One example of an antibody-mediated disease for which the cognate antigen is known is MG. Although MG symptoms are due to antibody binding to muscle AChR, circumstantial and direct evidence suggests that CD4⁺ T helper cells have an important role in the pathogenesis of human MG. The presence of high-affinity anti-AChR IgG antibodies implies that T helper factors lead to a switch to synthesis of antibodies of the IgG isotype by the anti-AChR B cells and to "maturation" of their affinity. Second, anti-AChR reactive CD4⁺ T cells present in the blood and thymus of MG patients can be propagated *in vitro* from these tissues, and have T helper function. Third, the only obvious and early effect on the anti-AChR immune response of thymectomy--a staple in the treatment of MG--is an immediate and pronounced decrease in the anti-AChR reactivity of circulating T cells. Fourth,

5 treatment of MG patients with anti-CD4⁺ antibodies abolishes the T cell response *in vitro* to the AChR and causes clinical and electrophysiological improvement. Fifth, experiments carried out in a chimeric human-SCID mouse model of passively transferred MG demonstrated that CD4⁺ cells are indispensable for transfer of the symptoms, and that CD4⁺ cell lines, derived from MG patients and specific for individual universal epitopes of the α subunit of human AChR can drive the synthesis of pathogenic anti-AChR antibodies that cause MG symptoms.

10 Several studies have identified sequences of the human AChR α subunit recognized by T cells in MG patients. To determine whether the CD4⁺ cells recognizing those immunodominant and/or universal epitope sequences can drive the synthesis of pathogenic anti-AChR antibodies, and how the ability of the different sequence regions of the AChR to interact with different HLA DR molecules correlates with the presence of universal CD4⁺ epitopes, synthetic peptides based on the amino acid sequence of the human α subunit of AChR (Noda et al., Nature, 305, 818 (1983); Schoepfer et al., FEBS Lett., 226, 235 (1981)) were
15 prepared. The peptides were approximately 20 residues long, a length that compares with that of naturally processed class II-restricted epitopes, which are 9-14 residues. Extra residues at either end of the epitope sequence do not affect the attachment of the peptide to the binding cleft of the presenting HLA class II molecule, which is
20 open at both its ends. The peptides overlapped by 5-10 residues to reduce the risk of missing epitopes “broken” between peptides.

The response to individual overlapping synthetic AChR peptides spanning the sequence of each AChR subunit, of unselected blood CD4⁺ T cells, and of CD4⁺ T cell lines enriched with AChR-specific cells by culture *in vitro* with AChR
25 antigens, was tested. The use of those two cell populations has different advantages and limitations. AChR-specific CD4⁺ lines have strong, consistent responses to individual peptides that allow a clear-cut assessment of their epitope repertoire. However, they may have an epitope repertoire different from that of the original CD4⁺ population due to biased clonal propagation *in vitro*. Also, denatured forms of

the antigen such as synthetic and biosynthetic peptides, which are commonly used for propagation of CD4⁺ cells specific for rare antigens, may be processed into peptide epitopes different from those obtained from processing of the native antigen *in vivo* and may expand CD4⁺ clones irrelevant for the immune process *in vivo*. The use of unselected T cells or CD4⁺ T cells from the blood of MG patients avoids the risk of detecting a biased repertoire due to the selective clonal loss or enrichment, but, because of the low frequency of antigen-specific CD4⁺ cells, reliable testing of nonselected blood CD4⁺ T cells is not always successful, especially when assessing the response to individual epitopes.

Due to the “orthogonal” advantages and shortcomings of unselected blood CD4⁺ cells and of AChR-specific CD4⁺ lines, it was from the combined results of those two approaches that many AChR sequence regions forming CD4⁺ epitopes could be confidently identified. The response to the individual AChR peptides of the anti-AChR cell lines was tested by a proliferation assay, and that of unselected blood CD4⁺ cells by proliferation and enzyme-linked immunospot (ELISPOT) assays. The latter assay type detects the antigen-induced secretion of cytokines (e.g., IFN- γ) by individual CD4⁺ Th1 cells, demonstrating their role in the anti-AChR CD4⁺ response. These different approaches have given consistent and complementary results.

The results from these studies, and those of others, which identify sequence regions on each AChR sequence regions on each AChR subunit form CD4⁺ epitopes are summarized in Table 3. Each patient had an individual repertoire, yet a few sequences on each AChR subunit are recognized by all or most patients, irrespective of the MHC haplotype. The results of studies on the response of blood CD4⁺ cells indicated that those “universal” epitope sequences are recognized by high numbers of T cells. Thus, they should be considered both universal and immunodominant epitope peptide sequences (indicated by bold characters in Table 3). Their immunodominance may be related to easy cleavage and processing, and to the ability of human DR molecules to interact with many unrelated peptides.

Table 3. Sequence Segments of the α , β , γ , δ , and ϵ Subunits of Human Muscle AChR Forming Epitopes Frequently Recognized by CD4+ Cells in MG Patients

α Subunit ^a							
5	Region α 1-80	Region α 101- 168	Region α 191- 207	Region α 293- 337	Region α 387- 437		
	α 1-14	α 101- 120	α 191- 207	α 293- 308	α 387- 405		
	α 19-34	α 118- 137		α 304- 322	α 403- 421		
	α 32-51	α 135- 154		α 320- 337	α 419- 437		
10	α 48-67	α 151- 168					
	α 63-80						

β Subunit ^b							
15	Region β 16-50	Region β 181- 200	Region β 271- 290	Region β 316- 350	Region β 361- 425		
	β 16-35	β 181- 200	β 271- 290	β 316- 335	β 361- 380		
	β 31-50			β 331- 350	β 376- 395		
					β 391- 410		
20					β 406- 425		

5

γ Subunit ^c							
Region γ 30-49	Region γ 60-124	Region γ 135- 154	Region γ 248- 288	Region γ 297- 355	Region γ 366- 400	Region γ 411- 430	Region γ 470- 495
γ 30-49	γ 60-79	γ 135- 154	γ 248- 267	γ 297- 312	γ 366- 385	γ 411- 430	γ 470- 489
	γ75-94		γ 263- 273	γ 306- 325	γ 381- 400		γ 476- 495
	γ 90-109		γ 269- 288	γ321- 340			
	γ 105- 124			γ 336- 355			

10

δ Subunit ^d							
Region δ 1-20	Region δ 61-80	Region δ 91-185	Region δ 196-290	Region δ 346-392	Region δ 461-496		
δ 1-20	δ 61-80	δ 91-110	δ 196-215	δ 346-362	δ 461-480		
		δ 106-125	δ 213-230	δ 363-386	δ 476-496		
		δ 121-140	δ 226-245	δ 373-392			
		δ 136-155	δ 241-260				
		δ 151-170	δ 256-275				
		δ 166-185	δ 271-290				

15

ε Subunit							
Region ε51-70	Region ε91-110	Region ε121-170	Region ε231-320	Region ε351-370	Region ε431-473		
5	ε51-70	ε91-110	ε121-140	ε231-250	ε351-370	ε431-450	
		ε141-160	ε241-260		ε451-470		
		ε151-170	ε261-280		ε461-473		
			ε281-300				
			ε291-310				
10			ε301-320				

- a From Manfredi et al., Neurology, 42, 1092 (1992); Protti et al., Proc. Natl. Acad. Sci. USA, 87, 7792 (1990); and Wang et al., 1997.
- b From Moiola et al., J. Immunol., 152, 4686 (1994).
- 15 c From Manfredi et al., J. Clin. Investig., 92, 1055 (1993); and Protti et al., J. Clin. Investig., 90, 1558 (1992).
- d From Manfredi et al., J. Clin. Investig., 92, 1055 (1993); and Protti et al., J. Immunol., 146, 2253 (1991).

20

Four AChR α subunit sequences-- α 48-67, α 101-137, α 304-322, and the carboxyl-terminal sequence α 403-437--are recognized by the majority of the patients, irrespective of their HLA class II type, and by a high number of cells. The peptide sequences recognized by 50% or more of the MG patients are clustered in five sequence regions. One corresponds to residues 1-14; the second corresponds to residues α 48-80 and comprises peptides α 48-67 and α 63-80; the third corresponds to residues α 101-154 and includes peptides α 101-120, α 118-137, and α 135-154; the

fourth corresponds to residues α 304-337 and includes peptides α 304-322 and α 320-337; and the fifth corresponds to residues α 403-437 and includes peptides α 403-421 and α 419-437. Most of the α subunit sequences recognized by the CD4⁺ cells correlate with the sequence regions that form non-transmembrane domains, which are believed to be at least partially exposed on the AChR surface. The α 48-80 sequence neighbors with, and includes, residues α 67-76, which are involved in formation of the MIR. The MIR is a relatively small surface area of the AChR that dominates the antibody response in human MG and rodent EMG. The sequence region α 101-154 includes a putative extracellular sequence region between two cysteine residues at positions 128 and 142, which must be at least partially exposed on the AChR surface because it is glycosylated.

The amino-terminus of all AChR subunits is extracellular, although it is not clear whether it is exposed on the AChR surface because it is accessible to the binding of antibody only after mild denaturation of the AChR. The fifth region, α 403-407, includes both the carboxyl-terminal end of the α subunit (residues α 428-437), which is hydrophilic and likely exposed on the extracellular surface, and the hydrophobic segment α 409-427, which is believed to form a transmembrane α helix, called M4. Three other transmembrane segments are believed to exist in α and in the other AChR subunits, called M1 (residues α 211-236), M2 (residues α 242-261), and M3 (residues α 277-298). These putative transmembrane regions largely correspond to three peptides that were recognized by the CD4⁺ cells of MG patients; α 214-234, α 246-264, and α 280-297. Hydrophobic sequences in the core of a protein may form epitopes and possibly universal immunodominant epitope sequences for human CD4⁺T cells, provided that they are flanked by sequence loops exposed on the surface of the molecule and accessible to the processing enzymes.

Short-term polyclonal lines specific for the universal AChR sequence regions can be easily propagated *in vitro* by cycles of stimulation with synthetic AChR peptides. Given the short time of propagation and the limited potential for biased clonal selection, they should be representative of the clonal repertoire of the

CD4⁺ cells recognizing epitopes within each immunodominant sequence region. Those lines were challenged with single residue-substituted analogues of the relevant immunodominant sequence regions to define the residues involved in formation of “universal” epitopes, to obtain clues about the clonality of the lines, and (if they are polyclonal) to understand whether they recognize one epitope or different overlapping epitopes: the response to the peptide analogues of polyclonal lines recognizing overlapping epitopes would be abolished by substitutions of “core” residues, common to all epitopes, and only partially affected by substitutions of residues included in some, but not all, epitopes.

Four peptides forming universal epitopes, α 48-67, α 304-322, γ 75-94, and γ 321-340, were examined. In the same patient, the CD4⁺ T cells recognizing a given universal epitope were polyclonal and recognized overlapping epitopes: their response was abolished by some substitutions, identifying residues common to all epitopes within a given region, while other substitutions residues (but did not obliterate) the response, indicating residues included in some, but not all, epitopes recognized by the line. Comparison of the residues involved in epitope formation for different lines supported the conclusion that, within the 20-residue peptides that were investigated, the same sequence segment is involved in formation of universal epitope(s) in DR-discordant patients. Within region α 48-67, the segment 55-63 contained most or all of the residues involved in T cell activation for all lines from two different patients (DR4/w53 and DR7/w53 restricted). Within the region α 304-322, residues 311-318 were involved in formation of all or most of the epitopes recognized by four lines from two different patients, both DR4/w53 restricted. Epitope recognition by one line from each patient was susceptible to substitutions outside the segment α 311-318. Within region γ 75-94, the segment 76-88 contained all residues involved in epitope(s) formation for three different patients, restricted by DR2/w51 and DR1. Within region γ 321-340, the segment 324-332 contained residues involved in epitope formation for three lines from two different patients, all restricted by DR2/w51.

Some AChR epitopes dominate also the sensitization of CD4⁺ cells in mice, and tolerization of the CD4⁺ cells recognizing even just one of those dominant epitopes can protect from development of EMG. On the other hand, other AChR sequences sensitize mouse CD4⁺ cells of lesser or no pathogenic potential, whose tolerization does not affect EMG development. To understand whether similar epitope-specific tolerization of pathogenic CD4⁺ cells could be suitable for the treatment of MG, it was determined whether the immunodominant universal sequences described above are recognized by CD4⁺ cells able to drive the synthesis of pathogenic antibodies.

The chimeric human-SCID mouse model of MG was used. The effects on appearance of human IgG, anti-AChR antibodies, and MG symptoms of engraftment into SCID mice of PBMC, CD4⁺-depleted PBMC from the same patient, or CD4⁺-depleted PBMC supplemented with a CD4⁺ line from the same patient that was specific for a given immunodominant universal epitope of the α subunit was determined. The lines were propagated by cycles of stimulations *in vitro* with the individual 20-residue synthetic peptides, corresponding to a given α subunit universal CD4⁺ epitope. As controls, DTD- or TTD-specific CD4⁺ lines from the same patients were used.

SCID mice engrafted with PBMC developed anti-AChR antibodies and myasthenic symptoms, while the mice engrafted with CD4⁺-depleted PBMC or with PBMC supplemented with CD4⁺ cell lines specific for DTD or TTD did not present myasthenic weakness. Addition to the CD4⁺-depleted PBMC of any (but one) of the CD4⁺ cell lines specific for α subunit universal epitopes induced myasthenic weakness in 25-50% of the engrafted mice and appearance of human anti-AChR antibody in the serum and at the neuromuscular junction of most mice.

Those findings clearly demonstrate that most of the anti-AChR CD4⁺ T cells specific for the universal epitope of the α subunit can drive the synthesis of pathogenic anti-AChR antibodies that cause myasthenic weakness and strongly support an important role of those universal sequence regions in the pathogenesis of

MG. Those results underline the usefulness of synthetic epitope sequences for the propagation and study of autoimmune CD4⁺ cells of pathogenic relevance.

IV. Preparation of the Peptides of the Invention

5 A. Nucleic Acid Molecules of the Invention

1. Sources of the Nucleic Acid Molecules of the Invention

Sources of nucleotide sequences from which a nucleic acid molecule encoding a peptide or variant thereof of the invention, or a variant thereof, include total or polyA⁺ RNA from any eukaryotic, preferably mammalian, cellular source
10 from which cDNAs can be derived by methods known in the art. Other sources of DNA molecules of the invention include genomic libraries derived from any eukaryotic cellular source.

Sources of nucleotide sequences of viral vectors useful in gene therapy include RNA or DNA from virally-infected cells, plasmids having DNA encoding
15 viral proteins, nucleic acid in viral particles and the like.

Moreover, the present DNA molecules may be prepared *in vitro*, e.g., by synthesizing an oligonucleotide of about 100, preferably about 75, more preferably about 50, and even more preferably about 40, nucleotides in length, or by subcloning a portion of a DNA segment that encodes a particular peptide.
20

2. Isolation of a Gene Encoding a Peptide of the Invention

A nucleic acid molecule encoding a peptide of the invention can be identified and isolated using standard methods, as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY (1989). For
25 example, reverse-transcriptase PCR (RT-PCR) can be employed to isolate and clone a preselected cDNA. Oligo-dT can be employed as a primer in a reverse transcriptase reaction to prepare first-strand cDNAs from isolated RNA which contains RNA sequences of interest, e.g., total RNA isolated from human tissue. RNA can be isolated by methods known to the art, e.g., using TRIZOL™ reagent

(GIBCO-BRL/Life Technologies, Gaithersburg, MD). Resultant first-strand cDNAs are then amplified in PCR reactions.

“Polymerase chain reaction” or “PCR” refers to a procedure or technique in which amounts of a preselected fragment of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Patent No. 4,683,195. Generally, sequence information from the ends of the region of interest or beyond is employed to design oligonucleotide primers comprising at least 7-8 nucleotides. These primers will be identical or similar in sequence to opposite strands of the template to be amplified. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, and the like. See generally Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51, 263 (1987); Erlich, ed., PCR Technology, (Stockton Press, NY, 1989). Thus, PCR-based cloning approaches rely upon conserved sequences deduced from alignments of related gene or polypeptide sequences.

Primers are made to correspond to highly conserved regions of polypeptides or nucleotide sequences which were identified and compared to generate the primers, e.g., by a sequence comparison of a particular eukaryotic gene. One primer is prepared which is predicted to anneal to the antisense strand, and another primer prepared which is predicted to anneal to the sense strand, of a nucleic acid molecule which encodes the preselected peptide.

The products of each PCR reaction are separated via an agarose gel and all consistently amplified products are gel-purified and cloned directly into a suitable vector, such as a known plasmid vector. The resultant plasmids are subjected to restriction endonuclease and dideoxy sequencing of double-stranded plasmid DNAs. Alternatively, isolated gel-purified fragments may be directly sequenced.

As used herein, the terms “isolated and/or purified” refer to *in vitro* isolation of a DNA, peptide or polypeptide molecule from its natural cellular environment, and from association with other components of the cell, such as nucleic acid or polypeptide, so that it can be sequenced, replicated, and/or expressed. For example,

an “isolated, preselected nucleic acid” is RNA or DNA containing greater than 9,
preferably 36, and more preferably 45 or more, sequential nucleotide bases that
encode at least a portion of a peptide of the invention, or a variant thereof, or a RNA
or DNA complementary thereto, that is complementary or hybridizes, respectively,
5 to RNA or DNA encoding the peptide, or polypeptide having said peptide, and
remains stably bound under stringent conditions, as defined by methods well known
in the art, e.g., in Sambrook et al., *supra*. Thus, the RNA or DNA is “isolated” in
that it is free from at least one contaminating nucleic acid with which it is normally
associated in the natural source of the RNA or DNA and is preferably substantially
10 free of any other mammalian RNA or DNA. The phrase “free from at least one
contaminating source nucleic acid with which it is normally associated” includes the
case where the nucleic acid is reintroduced into the source or natural cell but is in a
different chromosomal location or is otherwise flanked by nucleic acid sequences
not normally found in the source cell. An example of an isolated nucleic acid
15 molecule of the invention is RNA or DNA (e.g., SEQ ID NO:1) that encodes human
AChR (SEQ ID NO:2), or a fragment or subunit thereof, and shares at least about
80%, preferably at least about 90%, and more preferably at least about 95%,
contiguous sequence identity with the human AChR polypeptide.

As used herein, the term “recombinant nucleic acid” or “preselected nucleic
20 acid,” e.g., “recombinant DNA sequence or segment” or “preselected DNA
sequence or segment” refers to a nucleic acid, e.g., to DNA, that has been derived or
isolated from any appropriate tissue source, that may be subsequently chemically
altered *in vitro*, so that its sequence is not naturally occurring, or corresponds to
naturally occurring sequences that are not positioned as they would be positioned in
25 a genome which has not been transformed with exogenous DNA. An example of
preselected DNA “derived” from a source, would be a DNA sequence that is
identified as a useful fragment within a given organism, and which is then
chemically synthesized in essentially pure form. An example of such DNA
“isolated” from a source would be a useful DNA sequence that is excised or

removed from said source by chemical means, e.g., by the use of restriction endonucleases, so that it can be further manipulated, e.g., amplified, for use in the invention, by the methodology of genetic engineering.

Thus, recovery or isolation of a given fragment of DNA from a restriction
5 digest can employ separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. See Lawn et al., Nucleic Acids Res., 9, 6103 (1981), and Goeddel et al.,
10 Nucleic Acids Res., 8, 4057 (1980). Therefore, "preselected DNA" includes completely synthetic DNA sequences, semi-synthetic DNA sequences, DNA sequences isolated from biological sources, and DNA sequences derived from RNA, as well as mixtures thereof.

As used herein, the term "derived" with respect to a RNA molecule means
15 that the RNA molecule has complementary sequence identity to a particular DNA molecule.

3. Variants of the Nucleic Acid Molecules of the Invention

Nucleic acid molecules encoding amino acid sequence variants of a peptide
20 of the invention are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the
25 preselected peptide.

Oligonucleotide-mediated mutagenesis is a preferred method for preparing amino acid substitution variants of a peptide. This technique is well known in the art as described by Adelman et al., DNA, 2, 183 (1983). Briefly, DNA is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template,

where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the
5 selected alteration in the preselected DNA.

Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the
10 single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al., Proc. Natl. Acad. Sci. U.S.A., 75, 5765 (1978).

The DNA template can be generated by those vectors that are either derived from bacteriophage M13 vectors (the commercially available M13mp18 and
15 M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage origin of replication as described by Viera et al., Meth. Enzymol., 153, 3 (1987). Thus, the DNA that is to be mutated may be inserted into one of these vectors to generate single-stranded template. Production of the single-stranded template is described in Sections 4.21-4.41 of Sambrook et al., Molecular Cloning: A
20 Laboratory Manual (Cold Spring Harbor Laboratory Press, N.Y. 1989).

Alternatively, single-stranded DNA template may be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.

For alteration of the native DNA sequence (to generate amino acid sequence variants, for example), the oligonucleotide is hybridized to the single-stranded
25 template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of the peptide, and the other strand (the original template)

encodes the native, unaltered sequence of the peptide. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as *E. coli* JM101. After the cells are grown, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabeled with 32-phosphate to identify the bacterial colonies that contain the mutated DNA. The mutated region is then removed and placed in an appropriate vector for peptide or polypeptide production, generally an expression vector of the type typically employed for transformation of an appropriate host.

The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), is combined with a modified thiodeoxyribocytosine called dCTP-(aS) (which can be obtained from the Amersham Corporation). This mixture is added to the template-oligonucleotide complex. Upon addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. In addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion.

After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with ExoIII nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This homoduplex molecule can then be transformed into a suitable host cell such as *E. coli* JM101.

For example, a preferred embodiment of the invention is an isolated and purified DNA molecule comprising a preselected DNA segment, e.g., having SEQ ID NO:1, encoding a peptide of human AChR, wherein the DNA segment has nucleotide substitutions which are "silent" (see Figure 9). That is, when silent nucleotide substitutions are present in a codon, the same amino acid is encoded by the codon with the nucleotide substitution as is encoded by the codon without the substitution. For example, leucine is encoded by the codon CTT, CTC, CTA and CTG. A variant of SEQ ID NO:1 at the sixth codon in AChR (CTC in SEQ ID NO:1) includes the substitution of CTT, CTA or CTG for CTC. Other "silent" nucleotide substitutions in SEQ ID NO:1 which can encode a peptide having a sequence corresponding to a contiguous portion of SEQ ID NO:2 can be ascertained by reference to Figure 9 and page D1 in Appendix D in Sambrook et al., Molecular Cloning: A Laboratory Manual (1989). Nucleotide substitutions can be introduced into DNA segments by methods well known to the art. See, for example, Sambrook et al., *supra*. Likewise, nucleic acid molecules encoding other mammalian, preferably human, or viral, peptides may be modified in a similar manner, so as to yield nucleic acid molecules of the invention having silent nucleotide substitutions, or to yield nucleic acid molecules having nucleotide substitutions that result in amino acid substitutions (see peptide variants hereinbelow).

4. Chimeric Expression Cassettes

To prepare expression cassettes for transformation herein, the recombinant or preselected DNA sequence or segment may be circular or linear, double-stranded or single-stranded. Generally, the preselected DNA sequence or segment is in the form of chimeric DNA, such as plasmid DNA, that can also contain coding regions flanked by control sequences which promote the expression of the preselected DNA present in the resultant cell line.

As used herein, "chimeric" means that a vector comprises DNA from at least two different species, or comprises DNA from the same species, which is linked or

associated in a manner which does not occur in the “native” or wild type of the species.

Aside from preselected DNA sequences that serve as transcription units for a peptide, or portions thereof, a portion of the preselected DNA may be untranscribed, serving a regulatory or a structural function. For example, the preselected DNA may itself comprise a promoter that is active in mammalian cells, or may utilize a promoter already present in the genome that is the transformation target. Such promoters include the CMV promoter, as well as the SV40 late promoter and retroviral LTRs (long terminal repeat elements), although many other promoter elements well known to the art may be employed in the practice of the invention.

Other elements functional in the host cells, such as introns, enhancers, polyadenylation sequences and the like, may also be a part of the preselected DNA. Such elements may or may not be necessary for the function of the DNA, but may provide improved expression of the DNA by affecting transcription, stability of the mRNA, or the like. Such elements may be included in the DNA as desired to obtain the optimal performance of the transforming DNA in the cell.

“Control sequences” is defined to mean DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotic cells, for example, include a promoter, and optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

“Operably linked” is defined to mean that the nucleic acids are placed in a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a peptide or polypeptide if it is expressed as a preprotein that participates in the secretion of the peptide or polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

The preselected DNA to be introduced into the cells further will generally contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of transformed cells from the population of cells sought to be transformed. Alternatively, the selectable marker may be carried on a separate piece of DNA and used in a co-transformation procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers are well known in the art and include, for example, antibiotic and herbicide-resistance genes, such as *neo*, *hpt*, *dhfr*, *bar*, *aroA*, *dapA* and the like. See also, the genes listed on Table 1 of Lundquist et al. (U.S. Patent No. 5,848,956).

Reporter genes are used for identifying potentially transformed cells and for evaluating the functionality of regulatory sequences. Reporter genes which encode for easily assayable proteins are well known in the art. In general, a reporter gene is a gene which is not present in or expressed by the recipient organism or tissue and which encodes a protein whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Preferred genes include the chloramphenicol acetyl transferase gene (*cat*) from Tn9 of *E. coli*, the beta-glucuronidase gene (*gus*) of the *uidA* locus of *E. coli*, and the luciferase gene from firefly *Photinus pyralis*. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells.

The general methods for constructing recombinant DNA which can transform target cells are well known to those skilled in the art, and the same compositions and methods of construction may be utilized to produce the DNA useful herein. For example, J. Sambrook et al., Molecular Cloning: A Laboratory

Manual, Cold Spring Harbor Laboratory Press (2d ed., 1989), provides suitable methods of construction.

5. Transformation into Host Cells

5 The recombinant DNA can be readily introduced into the host cells, e.g., mammalian, bacterial, yeast or insect cells by transfection with an expression vector comprising DNA encoding a preselected peptide by any procedure useful for the introduction into a particular cell, e.g., physical or biological methods, to yield a transformed cell having the recombinant DNA stably integrated into its genome, so
10 that the DNA molecules, sequences, or segments, of the present invention are expressed by the host cell.

Physical methods to introduce a preselected DNA into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Biological methods to introduce the DNA of interest
15 into a host cell include the use of DNA and RNA viral vectors. The main advantage of physical methods is that they are not associated with pathological or oncogenic processes of viruses. However, they are less precise, often resulting in multiple copy insertions, random integration, disruption of foreign and endogenous gene sequences, and unpredictable expression. For mammalian gene therapy, it is
20 desirable to use an efficient means of precisely inserting a single copy gene into the host genome. Viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian, e.g., human cells. Other viral vectors can be derived from poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like. See, for example, U.S. Patent Nos.
25 5,350,674 and 5,585,362.

As used herein, the term "cell line" or "host cell" is intended to refer to well-characterized homogenous, biologically pure populations of cells. These cells may be eukaryotic cells that are neoplastic or which have been "immortalized" *in vitro* by methods known in the art, as well as primary cells, or prokaryotic cells. The cell

line or host cell is preferably of mammalian origin, but cell lines or host cells of non-mammalian origin may be employed, including plant, insect, yeast, fungal or bacterial sources. Generally, the preselected DNA sequence is related to a DNA sequence which is resident in the genome of the host cell but is not expressed, or not
5 highly expressed, or, alternatively, overexpressed.

“Transfected” or “transformed” is used herein to include any host cell or cell line, the genome of which has been altered or augmented by the presence of at least one preselected DNA sequence, which DNA is also referred to in the art of genetic engineering as “heterologous DNA,” “recombinant DNA,” “exogenous DNA,”
10 “genetically engineered,” “non-native,” or “foreign DNA,” wherein said DNA was isolated and introduced into the genome of the host cell or cell line by the process of genetic engineering. The host cells of the present invention are typically produced by transfection with a DNA sequence in a plasmid expression vector, a viral expression vector, or as an isolated linear DNA sequence. Preferably, the
15 transfected DNA is a chromosomally integrated recombinant DNA sequence, which comprises a gene encoding the peptide, which host cell may or may not express significant levels of autologous or “native” polypeptide.

To confirm the presence of the preselected DNA sequence in the host cell, a variety of assays may be performed. Such assays include, for example, “molecular
20 biological” assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; “biochemical” assays, such as detecting the presence or absence of a particular peptide, e.g., by immunological means (ELISAs and Western blots) or by assays described hereinabove to identify agents falling within the scope of the invention.

25 To detect and quantitate RNA produced from introduced preselected DNA segments, RT-PCR may be employed. In this application of PCR, it is first necessary to reverse transcribe RNA into DNA, using enzymes such as reverse transcriptase, and then through the use of conventional PCR techniques amplify the DNA. In most instances PCR techniques, while useful, will not demonstrate

integrity of the RNA product. Further information about the nature of the RNA product may be obtained by Northern blotting. This technique demonstrates the presence of an RNA species and gives information about the integrity of that RNA. The presence or absence of an RNA species can also be determined using dot or slot blot Northern hybridizations. These techniques are modifications of Northern blotting and only demonstrate the presence or absence of an RNA species.

While Southern blotting and PCR may be used to detect the preselected DNA segment in question, they do not provide information as to whether the preselected DNA segment is being expressed. Expression may be evaluated by specifically identifying the peptide products of the introduced preselected DNA sequences or evaluating the phenotypic changes brought about by the expression of the introduced preselected DNA segment in the host cell.

B. Peptides, Peptide Variants, and Derivatives Thereof

The present isolated, purified peptides or variants thereof, can be synthesized *in vitro*, e.g., by the solid phase peptide synthetic method or by recombinant DNA approaches (see above). The solid phase peptide synthetic method is an established and widely used method, which is described in the following references: Stewart et al., Solid Phase Peptide Synthesis, W. H. Freeman Co., San Francisco (1969); Merrifield, J. Am. Chem. Soc., 85 2149 (1963); Meienhofer in "Hormonal Proteins and Peptides," ed.; C.H. Li, Vol. 2 (Academic Press, 1973), pp. 48-267; and Bavaay and Merrifield, "The Peptides," eds. E. Gross and F. Meienhofer, Vol. 2 (Academic Press, 1980) pp. 3-285. These peptides can be further purified by fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an anion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; or ligand affinity chromatography.

Once isolated and characterized, derivatives, e.g., chemically derived derivatives, of a given peptide can be readily prepared. For example, amides of the

peptide or peptide variants of the present invention may also be prepared by techniques well known in the art for converting a carboxylic acid group or precursor to an amide. A preferred method for amide formation at the C-terminal carboxyl group is to cleave the peptide from a solid support with an appropriate amine, or to
5 cleave in the presence of an alcohol, yielding an ester, followed by aminolysis with the desired amine.

Salts of carboxyl groups of a peptide or peptide variant of the invention may be prepared in the usual manner by contacting the peptide with one or more equivalents of a desired base such as, for example, a metallic hydroxide base, e.g.,
10 sodium hydroxide; a metal carbonate or bicarbonate base such as, for example, sodium carbonate or sodium bicarbonate; or an amine base such as, for example, triethylamine, triethanolamine, and the like.

N-acyl derivatives of an amino group of the peptide or peptide variants may be prepared by utilizing an N-acyl protected amino acid for the final condensation,
15 or by acylating a protected or unprotected peptide. O-acyl derivatives may be prepared, for example, by acylation of a free hydroxy peptide or peptide resin. Either acylation may be carried out using standard acylating reagents such as acyl halides, anhydrides, acyl imidazoles, and the like. Both N- and O-acylation may be carried out together, if desired.

20 Formyl-methionine, pyroglutamine and trimethyl-alanine may be substituted at the N-terminal residue of the peptide or peptide variant. Other amino-terminal modifications include aminooxypentane modifications (see Simmons et al., Science, 276, 276 (1997)).

In addition, the amino acid sequence of a peptide can be modified so as to
25 result in a peptide variant (see above). The modification includes the substitution of at least one amino acid residue in the peptide for another amino acid residue, including substitutions which utilize the D rather than L form, as well as other well known amino acid analogs. These analogs include phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate;

hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4,-
tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, α -
methyl-alanine, para-benzoyl-phenylalanine, phenylglycine, propargylglycine,
sarcosine, and tert-butylglycine.

- 5 One or more of the residues of the peptide can be altered, so long as the
peptide variant is biologically active. For example, it is preferred that the variant
has at least about 10% of the biological activity of the corresponding non-variant
peptide. Conservative amino acid substitutions are preferred--that is, for example,
aspartic-glutamic as acidic amino acids; lysine/arginine/histidine as basic amino
10 acids; leucine/isoleucine, methionine/valine, alanine/valine as hydrophobic amino
acids; serine/glycine/alanine/threonine as hydrophilic amino acids.

- Conservative substitutions are shown in Figure 10 under the heading of
exemplary substitutions. More preferred substitutions are under the heading of
preferred substitutions. After the substitutions are introduced, the variants are
15 screened for biological activity.

- Amino acid substitutions falling within the scope of the invention, are, in
general, accomplished by selecting substitutions that do not differ significantly in
their effect on maintaining (a) the structure of the peptide backbone in the area of
the substitution, (b) the charge or hydrophobicity of the molecule at the target site,
20 or (c) the bulk of the side chain. Naturally occurring residues are divided into
groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- 25 (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic; trp, tyr, phe.

The invention also envisions peptide variants with non-conservative substitutions. Non-conservative substitutions entail exchanging a member of one of the classes described above for another.

5 Acid addition salts of the peptide or variant peptide, or of amino residues of the peptide or variant peptide, may be prepared by contacting the peptide or amine with one or more equivalents of the desired inorganic or organic acid, such as, for example, hydrochloric acid. Esters of carboxyl groups of the peptides may also be prepared by any of the usual methods known in the art.

10

V. Dosages, Formulations and Routes of Administration of the Peptides of the Invention

 The peptides or nucleic acid molecules of the invention, including their salts, are preferably administered so as to achieve a reduction in at least one symptom
15 associated with a particular indication or disease, a decrease in the amount of antibody associated with the indication or disease, and/or a decreased responsiveness of CD4+ cells to the administered peptide or corresponding antigen. To achieve this effect(s), the peptide, a variant thereof or a combination thereof, agent may be administered at dosages of at least about 0.001 to about 100 mg/kg,
20 more preferably about 0.01 to about 10 mg/kg, and even more preferably about 0.1 to about 5 mg/kg, of body weight, although other dosages may provide beneficial results. The amount administered will vary depending on various factors including, but not limited to, the agent chosen, the disease, the weight, the physical condition, and the age of the mammal, whether prevention or treatment is to be achieved, and if
25 the agent is chemically modified. Such factors can be readily determined by the clinician employing animal models or other test systems which are well known to the art.

 Administration of sense nucleic acid molecule may be accomplished through the introduction of cells transformed with an expression cassette comprising the

nucleic acid molecule (see, for example, WO 93/02556) or the administration of the nucleic acid molecule (see, for example, Felgner et al., U.S. Patent No. 5,580,859, Pardoll et al., Immunity, 3, 165 (1995); Stevenson et al., Immunol. Rev., 145, 211 (1995); Molling, J. Mol. Med., 75, 242 (1997); Donnelly et al., Ann. N.Y. Acad. Sci., 772, 40 (1995); Yang et al., Mol. Med. Today, 2, 476 (1996); Abdallah et al., Biol. Cell, 85, 1 (1995)). Pharmaceutical formulations, dosages and routes of administration for nucleic acids are generally disclosed, for example, in Felgner et al., *supra*.

Administration of the therapeutic agents in accordance with the present invention may be continuous or intermittent, depending, for example, upon the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners. The administration of the agents of the invention may be essentially continuous over a preselected period of time or may be in a series of spaced doses. Both local and systemic administration is contemplated.

To prepare the composition, peptides are synthesized or otherwise obtained, purified and then lyophilized and stabilized. The peptide can then be adjusted to the appropriate concentration, and optionally combined with other agents. The absolute weight of a given peptide included in a unit dose of a tolerogen can vary widely. For example, about 0.01 to about 10 mg, preferably about 0.5 to about 5 mg, of at least one peptide of the invention, and preferably a plurality of peptides specific for a particular antigen, each containing a universal and/or immunodominant epitope sequence, can be administered. A unit dose of the tolerogen is preferably administered either via a mucous membrane, e.g., by respiratory, e.g., nasal (e.g., instill or inhale aerosol) or genitourinary tract administration, or orally, although other routes, such as subcutaneous and intraperitoneal are envisioned to be useful to induce tolerance.

Thus, one or more suitable unit dosage forms comprising the therapeutic agents of the invention, which, as discussed below, may optionally be formulated

for sustained release (for example using microencapsulation, see WO 94/ 07529, and U.S. Patent No. 4,962,091 the disclosures of which are incorporated by reference herein), can be administered by a variety of routes including oral, or parenteral, including by rectal, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, intrathoracic, intrapulmonary and intranasal (respiratory) routes. The formulations may, where appropriate, be conveniently presented in discrete unit dosage forms and may be prepared by any of the methods well known to pharmacy. Such methods may include the step of bringing into association the therapeutic agent with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, introducing or shaping the product into the desired delivery system.

When the therapeutic agents of the invention are prepared for oral administration, they are preferably combined with a pharmaceutically acceptable carrier, diluent or excipient to form a pharmaceutical formulation, or unit dosage form. Preferably, orally administered therapeutic agents of the invention are formulated for sustained release, e.g., the agents are microencapsulated. The total active ingredients in such formulations comprise from 0.1 to 99.9% by weight of the formulation. By "pharmaceutically acceptable" it is meant the carrier, diluent, excipient, and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof. The active ingredient for oral administration may be present as a powder or as granules; as a solution, a suspension or an emulsion; or in achievable base such as a synthetic resin for ingestion of the active ingredients from a chewing gum. The active ingredient may also be presented as a bolus, electuary or paste.

Pharmaceutical formulations containing the therapeutic agents of the invention can be prepared by procedures known in the art using well known and readily available ingredients. For example, the agent can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers

that are suitable for such formulations include the following fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose, HPMC and other cellulose derivatives, alginates, gelatin, and polyvinyl-pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols.

- 10 For example, tablets or caplets containing the agents of the invention can include buffering agents such as calcium carbonate, magnesium oxide and magnesium carbonate. Caplets and tablets can also include inactive ingredients such as cellulose, pregelatinized starch, silicon dioxide, hydroxy propyl methyl cellulose, magnesium stearate, microcrystalline cellulose, starch, talc, titanium dioxide, 15 benzoic acid, citric acid, corn starch, mineral oil, polypropylene glycol, sodium phosphate, and zinc stearate, and the like. Hard or soft gelatin capsules containing an agent of the invention can contain inactive ingredients such as gelatin, microcrystalline cellulose, sodium lauryl sulfate, starch, talc, and titanium dioxide, and the like, as well as liquid vehicles such as polyethylene glycols (PEGs) and 20 vegetable oil. Moreover, enteric coated caplets or tablets of an agent of the invention are designed to resist disintegration in the stomach and dissolve in the more neutral to alkaline environment of the duodenum.

- The therapeutic agents of the invention can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for 25 parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes.

The pharmaceutical formulations of the therapeutic agents of the invention can also take the form of an aqueous or anhydrous solution or dispersion, or alternatively the form of an emulsion or suspension.

Thus, the therapeutic agent may be formulated for parenteral administration (e.g., by injection, for example, bolus injection or continuous infusion) and may be presented in unit dose form in ampules, pre-filled syringes, small volume infusion containers or in multi-dose containers with an added preservative. The active ingredients may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredients may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.

These formulations can contain pharmaceutically acceptable vehicles and adjuvants which are well known in the art. It is possible, for example, to prepare solutions using one or more organic solvent(s) that is/are acceptable from the physiological standpoint, chosen, in addition to water, from solvents such as acetone, ethanol, isopropyl alcohol, glycol ethers such as the products sold under the name "Dowanol", polyglycols and polyethylene glycols, C₁-C₄ alkyl esters of short-chain acids, preferably ethyl or isopropyl lactate, fatty acid triglycerides such as the products marketed under the name "Miglyol", isopropyl myristate, animal, mineral and vegetable oils and polysiloxanes.

The compositions according to the invention can also contain thickening agents such as cellulose and/or cellulose derivatives. They can also contain gums such as xanthan, guar or carbo gum or gum arabic, or alternatively polyethylene glycols, bentones and montmorillonites, and the like.

It is possible to add, if necessary, an adjuvant chosen from antioxidants, surfactants, other preservatives, film-forming, keratolytic or comedolytic agents, perfumes and colorings. Also, other active ingredients may be added, whether for the conditions described or some other condition.

For example, among antioxidants, t-butylhydroquinone, butylated hydroxyanisole, butylated hydroxytoluene and α -tocopherol and its derivatives may

be mentioned. The galenical forms chiefly conditioned for topical application take the form of creams, milks, gels, dispersion or microemulsions, lotions thickened to a greater or lesser extent, impregnated pads, ointments or sticks, or alternatively the form of aerosol formulations in spray or foam form or alternatively in the form of a
5 cake of soap.

Additionally, the agents are well suited to formulation as sustained release dosage forms and the like. The formulations can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal or respiratory tract, possibly over a period of time. The coatings, envelopes, and
10 protective matrices may be made, for example, from polymeric substances, such as polylactide-glycolates, liposomes, microemulsions, microparticles, nanoparticles, or waxes. These coatings, envelopes, and protective matrices are useful to coat indwelling devices, e.g., stents, catheters, peritoneal dialysis tubing, and the like.

The therapeutic agents of the invention can be delivered via patches for
15 transdermal administration. See U.S. Patent No. 5,560,922 for examples of patches suitable for transdermal delivery of a therapeutic agent. Patches for transdermal delivery can comprise a backing layer and a polymer matrix which has dispersed or dissolved therein a therapeutic agent, along with one or more skin permeation enhancers. The backing layer can be made of any suitable material which is
20 impermeable to the therapeutic agent. The backing layer serves as a protective cover for the matrix layer and provides also a support function. The backing can be formed so that it is essentially the same size layer as the polymer matrix or it can be of larger dimension so that it can extend beyond the side of the polymer matrix or overlay the side or sides of the polymer matrix and then can extend outwardly in a
25 manner that the surface of the extension of the backing layer can be the base for an adhesive means. Alternatively, the polymer matrix can contain, or be formulated of, an adhesive polymer, such as polyacrylate or acrylate/vinyl acetate copolymer. For long-term applications it might be desirable to use microporous and/or breathable backing laminates, so hydration or maceration of the skin can be minimized.

Examples of materials suitable for making the backing layer are films of high and low density polyethylene, polypropylene, polyurethane, polyvinylchloride, polyesters such as poly(ethylene phthalate), metal foils, metal foil laminates of such suitable polymer films, and the like. Preferably, the materials used for the backing layer are laminates of such polymer films with a metal foil such as aluminum foil. In such laminates, a polymer film of the laminate will usually be in contact with the adhesive polymer matrix.

The backing layer can be any appropriate thickness which will provide the desired protective and support functions. A suitable thickness will be from about 10 to about 200 microns.

Generally, those polymers used to form the biologically acceptable adhesive polymer layer are those capable of forming shaped bodies, thin walls or coatings through which therapeutic agents can pass at a controlled rate. Suitable polymers are biologically and pharmaceutically compatible, nonallergenic and insoluble in and compatible with body fluids or tissues with which the device is contacted. The use of soluble polymers is to be avoided since dissolution or erosion of the matrix by skin moisture would affect the release rate of the therapeutic agents as well as the capability of the dosage unit to remain in place for convenience of removal.

Exemplary materials for fabricating the adhesive polymer layer include polyethylene, polypropylene, polyurethane, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylene/vinyl acetate copolymers, silicone elastomers, especially the medical-grade polydimethylsiloxanes, neoprene rubber, polyisobutylene, polyacrylates, chlorinated polyethylene, polyvinyl chloride, vinyl chloride-vinyl acetate copolymer, crosslinked polymethacrylate polymers (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), butyl rubber, epichlorohydrin rubbers, ethylenvinyl alcohol copolymers, ethylene-vinyloxyethanol copolymers; silicone copolymers, for example, polysiloxane-polycarbonate copolymers, polysiloxanepolyethylene oxide copolymers, polysiloxane-polymethacrylate copolymers, polysiloxane-alkylene copolymers (e.g.,

polysiloxane-ethylene copolymers), polysiloxane-alkylenesilane copolymers (e.g., polysiloxane-ethylenesilane copolymers), and the like; cellulose polymers, for example methyl or ethyl cellulose, hydroxy propyl methyl cellulose, and cellulose esters; polycarbonates; polytetrafluoroethylene; and the like.

- 5 Preferably, a biologically acceptable adhesive polymer matrix should be selected from polymers with glass transition temperatures below room temperature. The polymer may, but need not necessarily, have a degree of crystallinity at room temperature. Cross-linking monomeric units or sites can be incorporated into such polymers. For example, cross-linking monomers can be incorporated into
- 10 polyacrylate polymers, which provide sites for cross-linking the matrix after dispersing the therapeutic agent into the polymer. Known cross-linking monomers for polyacrylate polymers include polymethacrylic esters of polyols such as butylene diacrylate and dimethacrylate, trimethylol propane trimethacrylate and the like. Other monomers which provide such sites include allyl acrylate, allyl methacrylate,
- 15 diallyl maleate and the like.

- Preferably, a plasticizer and/or humectant is dispersed within the adhesive polymer matrix. Water-soluble polyols are generally suitable for this purpose. Incorporation of a humectant in the formulation allows the dosage unit to absorb moisture on the surface of skin which in turn helps to reduce skin irritation and to
- 20 prevent the adhesive polymer layer of the delivery system from failing.

- Therapeutic agents released from a transdermal delivery system must be capable of penetrating each layer of skin. In order to increase the rate of permeation of a therapeutic agent, a transdermal drug delivery system must be able in particular to increase the permeability of the outermost layer of skin, the stratum corneum,
- 25 which provides the most resistance to the penetration of molecules. The fabrication of patches for transdermal delivery of therapeutic agents is well known to the art.

 For topical administration, the therapeutic agents may be formulated as is known in the art for direct application to a target area. Conventional forms for this purpose include wound dressings, coated bandages or other polymer coverings,

ointments, creams, lotions, pastes, jellies, sprays, and aerosols. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more
5 emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. The active ingredients can also be delivered via iontophoresis, e.g., as disclosed in U.S. Patent Nos. 4,140,122; 4,383,529; or 4,051,842. The percent by weight of a therapeutic agent of the invention present in a topical formulation will depend on various factors, but generally will be from
10 0.01% to 95% of the total weight of the formulation, and typically 0.1-25% by weight.

Drops, such as eye drops or nose drops, may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilizing agents or suspending agents. Liquid sprays are conveniently delivered from
15 pressurized packs. Drops can be delivered via a simple eye dropper-capped bottle, or via a plastic bottle adapted to deliver liquid contents dropwise, via a specially shaped closure.

The therapeutic agent may further be formulated for topical administration in the mouth or throat. For example, the active ingredients may be formulated as a
20 lozenge further comprising a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the composition in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the composition of the present invention in a suitable liquid carrier.

Preferably, the peptide or nucleic acid of the invention is administered to the
25 respiratory tract. Thus, the present invention also provides aerosol pharmaceutical formulations and dosage forms for use in the methods of the invention. In general, such dosage forms comprise an amount of at least one of the agents of the invention effective to treat or prevent the clinical symptoms of a specific indication or disease. Any statistically significant attenuation of one or more symptoms of an indication or

disease that has been treated pursuant to the method of the present invention is considered to be a treatment of such indication or disease within the scope of the invention.

5 It will be appreciated that the unit content of active ingredient or ingredients contained in an individual aerosol dose of each dosage form need not in itself constitute an effective amount for treating the particular indication or disease since the necessary effective amount can be reached by administration of a plurality of dosage units. Moreover, the effective amount may be achieved using less than the dose in the dosage form, either individually, or in a series of administrations.

10 The pharmaceutical formulations of the present invention may include, as optional ingredients, pharmaceutically acceptable carriers, diluents, solubilizing or emulsifying agents, and salts of the type that are well-known in the art. Examples of such substances include normal saline solutions such as physiologically buffered saline solutions and water.

15 A preferred route of administration of the therapeutic agents of the present invention is in an aerosol or inhaled form. The agents of the present invention can be administered as a dry powder or in an aqueous solution. Preferred aerosol pharmaceutical formulations may comprise, for example, a physiologically acceptable buffered saline solution containing between about 0.1 mg/ml and about 20 100 mg/ml of one or more of the agents of the present invention specific for the indication or disease to be treated.

Dry aerosol in the form of finely divided solid peptide or nucleic acid particles that are not dissolved or suspended in a liquid are also useful in the practice of the present invention. Peptide or nucleic acid may be in the form of dusting 25 powders and comprise finely divided particles having an average particle size of between about 1 and 5 μm , preferably between 2 and 3 μm . Finely divided particles may be prepared by pulverization and screen filtration using techniques well known in the art. The particles may be administered by inhaling a predetermined quantity of the finely divided material, which can be in the form of a powder.

Specific non-limiting examples of the carriers and/or diluents that are useful in the pharmaceutical formulations of the present invention include water and physiologically acceptable buffered saline solutions such as phosphate buffered saline solutions pH 7.0-8.0.

- 5 For administration to the upper (nasal) or lower respiratory tract by inhalation, the therapeutic agents of the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, 10 carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Nebulizers include, but are not limited to, those described in U.S. Patent Nos. 4,624,251; 3,703,173; 3,561,444; and 4,635,627.

- Alternatively, for administration by inhalation or insufflation, the 15 composition may take the form of a dry powder, for example, a powder mix of the therapeutic agent and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges, or, e.g., gelatine or blister packs from which the powder may be administered with the aid of an inhalator, insufflator, or a metered-dose inhaler (see, 20 for example, the pressurized metered dose inhaler (MDI) and the dry powder inhaler disclosed in Newman, S. P. in Aerosols and the Lung, Clarke, S. W. and Davia, D. eds., pp. 197-224, Butterworths, London, England, 1984).

- Aerosol delivery systems of the type disclosed herein are available from numerous commercial sources including Fisons Corporation (Bedford, Mass.), 25 Schering Corp. (Kenilworth, NJ) and American Pharmoseal Co., (Valencia, CA).

For intra-nasal administration, the therapeutic agent may be administered via nose drops, a liquid spray, such as via a plastic bottle atomizer or metered-dose inhaler. Typical of atomizers are the Mistometer (Wintrop) and the Medihaler (Riker).

The formulations and compositions described herein may also contain other ingredients such as antimicrobial agents, or preservatives. Furthermore, the active ingredients may also be used in combination with other therapeutic agents, for example, bronchodilators.

5

VI. Management of Antibody-Mediated Disease

To treat an undesirable antibody-mediated immune response, such as the one in MG patients, universal and/or immunodominant epitopes are identified. MG is a disease that is diagnosed after a full sensitization of CD4+ cell to the AChR has occurred, and the synthesis of anti-AChR antibodies is actively occurring. To enhance the efficacy of peptide-based therapies, plasmapheresis is used in combination with the peptide treatment. Plasmapheresis "clears" the antibodies from the patient's blood, and it is in most cases associated with the administration of an immunosuppressant such as azathioprine, to help decrease the activity of the pathogenic immune cells. Thus, the administration of a peptide of the invention in combination with pheresis and optionally an immunosuppressant may be useful to manage MG as such a method would result in a long lasting down regulation of the anti-AChR response, in both the CD4+ and the B cell compartments.

In hemophilia A patients, a treatment similar to that described above for MG could be used for patients that have already developed antibody inhibitors to factor VIII. Moreover, the existence of universal CD4+ epitopes on the factor VIII molecule would allow the use of these approaches for the prevention of inhibitor development. Furthermore, the identification of universal CD4+ epitope sequences for factor VIII would allow their use for nasal tolerization procedures that would be suitable both in the treatment of established factor VIII inhibitors and in the prevention of inhibitor development, by tolerizing or down regulating the priming and/or activity of the T helper clones potentially reactive to factor VIII sequences, prior to the first therapeutic exposure to factor VIII in infancy.

Even if no universal CD4⁺ epitope sequences were identified on a given antigen, i.e. if every patient had a unique CD4⁺ repertoire, the peptides of the invention can provide the basis for tolerization to a given antigen towards the therapy of an undesirable antibody response. In the case of established immune resistance to factor VIII, the CD4⁺ repertoire of each patient is determined prior to "customizing" the tolerizing treatment to the epitopes recognized by that particular patient. This can be accomplished in about 6-8 weeks, at an estimated cost of \$20,000/patient. In contrast, the cost of immune tolerance induction using daily intravenous infusions of factor VIII over many months is about \$250,000/year per patient.

The invention will be further described by, but is not limited to, the following examples.

Example I

Prevention of Experimental Myasthenia Gravis by Nasal Administration of AChR T Epitope Sequences

Materials and Methods

Peptide Synthesis and Characterization. Three peptides, 19-20 residues in length, corresponding to residues 150-169, 181-200 and 360-378 of the TACHR α subunit, were synthesized by methods described in Houghton (1985). An additional three 20 residue peptides were synthesized, corresponding to residues 271-290, 321-340, and 431-450 of diphtheria toxin (DTX). These peptides were shown to be highly and universally immunogenic for human CD4⁺ T cells (Yeh et al., 1990).

Purification and Preparation of *Torpedo californica* AChR. TACHR was purified from *Torpedo californica* electric organ as alkali-stripped TACHR-rich membrane fragments, and characterized as described previously (Bellone et al., 1991). The TACHR concentration was determined as α -bungarotoxin (α BTX) binding sites (Schmidt et al., 1973). The protein concentration was determined by the Lowry assay (Lowry et al., 1981). The TACHR preparations contained 3.8-5.8

nmols of α BTX binding sites/mg protein. The protein composition was assessed by sodium dodecylsulphate polyacrylamide gel electrophoresis (Laemmli, 1970). The preparations employed herein consistently showed only the four TACHR subunits as the main protein bands.

- 5 For use in cell cultures, the TACHR-rich membrane fragments were diluted in RPMI-1640, and sterilized by UV irradiation.

For immunization, TACHR-rich membrane fragments were solubilized in 1% Triton X-100 (Bellone et al., 1991), diluted to 0.5 mg/ml in PBS and stored at -80°C.

- 10 Mice and Induction of Tolerance. B6 mice were purchased from Jackson Laboratory (Bar Harbor, ME) and housed at the animal facility of the University of Minnesota. After light anesthesia by i.m. injection of Ketaset (100 mg/kg; Alveco Co., Inc., Fort Dodge, IA), the mice received into both nostrils a total of 25 μ l of PBS containing 50 μ g of peptide T α 150-169, either alone or pooled with equimolar
15 amounts of peptides T α 180-200 and T α 360-378 (referred to as "peptide pool" or " α pool"). The dose was based on the results of an experiment in which increasing amounts of peptide α 150-169 were used (50 μ g, 100 μ g, 200 μ g, 400 μ g and 800 μ g). The lowest dose (50 μ g) afforded a satisfactory level of protection. The tolerogen was administered as a solution instilled into the nostrils, a method of delivery which
20 allowed accurate administration of a defined amount of solution. Nasal delivery of either aerosol or liquid antigen solutions has been shown to have similar efficacy in suppressing the effects of subsequent immunizations (Al-Sabbagh et al., 1996; Kuper et al., 1992; Liu et al., 1993; Husby et al., 1994; Neutra et al., 1996; Abbas et al., 1996; Conti-Fine et al., 1996; Karpus et al., 1996; Dick et al., 1993).

- 25 In protocol A, peptides or peptide-free PBS were administered two weeks before the first TACHR immunization, and then three more times, on the same day as the three immunizations with TACHR (at one month intervals, see below). In protocol B, peptides or peptide-free PBS were administered weekly, starting two

weeks before beginning of the immunization with TACHR, for a total of 14 treatments (two before and 12 during TACHR immunization).

Control mice received 25 µl of peptide-free PBS, or a pool of the three synthetic DTX peptides in PBS.

5 Immunizations. Eight-ten week old mice were immunized by subcutaneous injections, along the back and at the base of the tail, with solubilized TACHR (50 µg), peptide Tα150-169 (100 µg), or the peptide pool (100 µg of each peptide). The mice were boosted twice at 4 week intervals with the same amount of antigen. The antigen solutions (in 100 µl PBS) were emulsified with an equal volume of
10 complete Freund's adjuvant (FA) for the first injection, and with incomplete FA for the boosts. Control mice were injected with PBS emulsified in the appropriate adjuvant.

Evaluation of the Clinical Symptoms of EMG. EMG symptoms were quantified by a forced exercise using the inverted hang technique, sensitized by
15 administration of a minute amount of pancuronium bromide (0.03 mg/kg i.p.) just prior to the beginning of the test (Karachunski et al., 1995). The mice hang from a grid, and the time it takes for the mouse to release its hold and fall three times ("holding time") was measured. The test was performed on the day of the first nasal administration, on the day before each immunization, and 7-14 days after the third
20 immunization, just before sacrificing the animal. This test is parametric, and gives a quantitative assessment of the severity of the weakness.

To verify the myasthenic nature of the weakness observed, mice with significant weakness were injected i.p. with the cholinesterase inhibitor edrophonium chloride (Reversol, Organon Inc., West Orange, NJ). Reversol
25 immediately improved the strength of the animals, and alleviated the paralysis of the most severely affected mice. The test was performed blindly, i.e., without knowledge of the treatment that the mouse had received.

The holding time of normal mice was 10.4 ± 2.1 minutes (n=99). Mice with holding times of eight minutes or longer were considered normal, those with a

holding time of more than four minutes but less than eight minutes were considered to have moderate symptoms, and those with a holding time of less than four minutes were considered severely affected. Mice that were paralyzed or had died of respiratory paralysis are represented in the figures as having a holding time of zero.

5 Lymphocyte Proliferation Assay. Seven-ten days after the last immunization, spleen T cells were purified from individual mice (Bellone et al., 1991). Irradiated (3000 rad) spleen cells from non-immunized mice were diluted in RPMI-1640 (Gibco, Grand Island, NY) supplemented with 10% heat inactivated fetal calf serum (Gibco), 50 μ M 2-mercaptoethanol, 1 mM L-glutamine, 10 mM
10 Hepes, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 μ g/ml streptomycin (culture medium) and used as antigen presenting cells. The spleen T cells (1×10^6 cells/ml in culture medium, 100 μ l/well) were seeded in triplicate in 96 flat-bottom well plates containing 100 μ l of 5×10^6 /ml antigen presenting cells. One of the following Ag was added: 10 μ g/ml PHA (Sigma, St Louis, MO); 5 or 10 μ g/ml
15 TACHR; 5 or 10 μ g/ml of the individual peptides; increasing concentrations of pooled DTX peptides (2.5-20 μ g/ml of each peptide); or increasing concentrations of pooled DTX peptides (2.5-20 μ g/ml of each peptide) plus 10 μ g/ml TACHR. Controls were triplicate wells containing T and antigen presenting cells, without any antigen. After 4 days the cells were labeled for 16 hours with 3 H-thymidine (1 μ Ci
20 per well, specific activity 6.7 Ci/mmol, Dupont, Boston, MA) and harvested (Titertek, Skatron, Sterling, VA). 3 H-thymidine incorporation was measured by liquid scintillation. The data are represented as stimulation indexes (S.I.), namely the ratio between the c.p.m. obtained for a culture in the presence of a given stimulus, and the average c.p.m. obtained for the unstimulated cultures (blanks).

25 Determination of Cytokine Secretion in Response to TACHR by Mouse Spleen Cells *in vitro*. Seven-ten days after the last immunization, spleen cells were cultured as described above for the proliferation assay, using sextuplicate cultures, with and without 10 μ g/ml TACHR. Controls were triplicate cultures for each mouse group that did not receive any stimulus. After 12, 24 and 48 hours the

supernatants were harvested, and the IL-2 and IL-10 concentration was determined by capture ELISA using duplicate samples (Pharmigen, San Diego, CA). Anti-IL-2 and anti-IL-10 Ab, and recombinant IL-2 and IL-10 (Pharmigen), were employed as standards.

- 5 Effect of Pre-Incubation with IL-2 on the Response to TACHR by Mouse Spleen Cells *in vitro*. Spleen cells from mice tolerized to the α pool following protocol B, or sham-tolerized with PBS, and immunized with TACHR as described above, were incubated *in vitro* with or without 1 ng/ml of mouse recombinant IL-2 (Pharmigen) in TCM for 5 days in 25 ml flasks (Corning Costar, Cambridge, MA).
- 10 The cells were then tested in the proliferation assay described above, using 5 and 10 μ g/ml of TACHR.

- Anti-AChR Antibody Assay. Sera was obtained from the mice after each clinical testing. The serum concentration of anti-TACHR antibody was measured by RIPA using TACHR solubilized in Triton X-100 and labeled by the binding of 125 I-
- 15 α BTX (Bellone et al., 1991). The antibody concentration is expressed as μ M precipitated 125 I- α BTX.

Statistical Analysis. The level of significance of the differences of the average responses between two groups was determined by two tailed students' t test, using the program Excel.

20 Results

- Distribution in the Respiratory Tract of Solutions Administered Nasally. To determine which parts of the mouse respiratory system came in contact with solutions given nasally, a solution of ethidium bromide was employed. Ethidium bromide is absorbed through the mucosal lining of the respiratory tract and
- 25 fluoresces brightly under U.V. light. Two mice were anesthetized and 25 μ l of a 4% ethidium bromide solution in PBS was instilled into the nostrils. Ten-fifteen minutes later the animals were sacrificed by cervical dislocation. Their nasal cavities, larynx, trachea, bronchi and lungs were dissected, washed in PBS and examined under U.V. light for ethidium bromide staining. The mouse nostrils,

larynx and trachea were brightly stained by ethidium bromide administered by the same procedure employed to administer the peptide solutions. The staining was increasingly weaker in the bronchi, and only weak focal signals were present in the lung parenchyma.

- 5 T Cells from Mice Treated Nasally and Immunized with TACHR Peptides Do Not Respond *in vitro* to the Peptides or to TACHR. To assess the effect of nasal treatment with synthetic TACHR peptides on the ability of CD4⁺ cells to become sensitized to the same peptides, three groups of mice were nasally administered peptide T α 150-169, the α pool (5.0 μ g/peptide), or peptide-free PBS, following
10 protocol A. The mice were immunized three times with the peptide(s) used for the tolerization procedure, administered as subcutaneous immunizing injections in adjuvant. Seven-ten days after the last immunization, the spleen T cells of two mice tolerized with peptide T α 150-169, four mice tolerized with the peptide pool, and two sham-tolerized mice, were tested for their proliferative response *in vitro* to the
15 immunizing peptides and to the TACHR.

The results obtained within each group were highly consistent. Figure 1 shows the results obtained with one mouse from each group. The T cells of sham-tolerized mice had a good proliferative response *in vitro* to the immunizing peptide(s) and to TACHR, indicating that they recognize epitopes similar to those
20 originating from TACHR processing (Karachunski et al., 1995), while the T cells of peptide-tolerized mice did not respond to the immunizing peptides(s) or to TACHR.

- Nasal Administration of Synthetic AChR Epitopes Prevents Appearance of EMG Symptoms. Figure 2 summarizes the results obtained from testing the strength of mice treated nasally with the peptide epitopes and immunized with
25 TACHR. Two groups of mice were studied. One group was treated with the TACHR peptide(s) using protocol A (panel A) while another group was treated with the peptides using protocol B (panel B). Sham-tolerized (panel "PBS") were employed as controls. For each group, the results obtained for the same mice prior to TACHR immunization (panel "naive") is also shown. The results depicted in

Figure 2 were obtained eight or ten weeks after beginning the immunization, when the maximum frequency of EMG symptoms was detected. The results from the two time points were consistent.

In agreement with previous studies which found variable EMG frequency (20-70%) in TACHR immunized B6 mice (Conti-Fine et al., 1997), the frequency of EMG in the sham-tolerized groups varied. In one experiment, 17 of 19 (89%) mice developed EMG. In the experiments shown in Figure 2, all five sham-tolerized mice, and five of the ten sham-tolerized mice, had EMG symptoms, respectively.

When the tolerizing peptides were administered following protocol A, five of the 12 mice (42%) tolerized with peptide T α 150-169, and three of the eight mice (37%) treated with the α pool, developed EMG, as compared to 100% of the mice sham-tolerized in parallel (Figure 2A). When the tolerizing peptides were administered following protocol B, none of the mice that received nasal administration of peptide T α 150-169 had detectable weaknesses, and one mouse in the group treated with the peptide pool had a holding time barely below eight minutes at ten weeks. 50% of the sham-tolerized mice had EMG weakness (Figure 2B).

In both experiments shown in Figure 2, mice tolerized to peptide T α 150-169 and to the α pool had significantly longer holding times than the sham-tolerized mice.

Reduced T Cell Response to the Sequence T α 150-169 and to TACHR After Immunization With TACHR in Mice Treated Nasally With Peptide T α 150-169 or the α Pool. Mice used for the experiment shown in Figure 2B were sacrificed ten weeks after beginning the TACHR immunizations. The spleen T cells of each mouse were tested in a proliferation assay with TACHR and the individual peptides T α 150-169, T α 181-200 and T α 360-378. Figure 3 is organized in four panels, according to the challenging antigen used in the proliferation assay. Each panel summarizes the responses to the challenging antigen for sham-tolerized (PBS) mice, mice tolerized to α 150-169 or mice tolerized to the α pool.

All but one of the sham-tolerized mice responded well to TACHR (S.I.=10-29). Two mice died of EMG before the experiment could be carried out. Most peptide-treated mice responded to TACHR: their average responses (horizontal bars in Figure 3) were slightly lower than those of the sham-tolerized group. However, the difference was significant only for the mice tolerized to the α pool. All groups of mice treated nasally with TACHR peptides had lower proliferative responses to the TACHR than the control mice sham-tolerized in parallel, but the extent of the reduction varied in the different groups. The particular groups of peptide-tolerized mice shown in Figure 3 are representative of those that had the least reduction in proliferative response to TACHR. In most other groups, the reduction was much more substantial, and some of the α pool-tolerized mice had barely detectable or no proliferative responses to TACHR (e.g., see Figures 5B and 6).

The T cells of most sham-tolerized mice responded to peptide T α 150-169 but to a much lesser extent than to TACHR, because the anti-TACHR CD4⁺ T cells of B6 mice recognize several epitopes on sequence regions other than T α 150-169 (Bellone et al., 1991). The T cells of both peptide-treated groups responded to T α 150-169 significantly less than the sham-treated mice. Several mice did not respond to T α 150-169 (S.I.<1.5).

Peptides T α 181-200 and T α 360-378, which are much less immunogenic for CD4⁺ cell sensitization than T α 150-169 (Karachunski et al., 1995), were recognized poorly even by the spleen T cells of sham-tolerized mice. Previous reports demonstrated that the T cell response of B6 mice to those epitope sequences can be detected only when using purified CD4⁺ cells instead of total spleen T cells (Bellone et al., 1991). The response to peptides T α 181-200 and T α 360-378 of the α pool-tolerized mice was the same as that of the control mice. Thus, the reduced T cell recognition of the TACHR molecule of the mice tolerized with the peptide pool is at least partially due to a reduced response to epitopes formed by the sequence T α 150-169.

The extent of the proliferative response to TACHR, T α 150-160 and T α 180-200 of the sham-tolerized mice correlated loosely with the presence of EMG symptoms. The three mice with EMG symptoms were among those with the highest S.I.

5 Nasal Treatment with AChR Peptides Causes Reduced Synthesis of
TACHR Antibody. The serum anti-TACHR antibody concentration of individual
mice tolerized with peptide T α 150-169, tolerized with the α pool or sham-tolerized,
four, eight and ten weeks after the beginning of the immunization with TACHR was
determined (Figure 4). Mice treated with T α 150-169 or the α pool had significantly
10 lower concentrations of anti-TACHR antibody than the sham-treated (PBS) group as
early as 4 weeks after the first TACHR immunization, although they eventually
developed substantial concentrations of anti-TACHR antibody (at ten weeks $5.5 \pm$
 $1.5 \mu\text{M}$ and $4.3 \pm 1.6 \mu\text{M}$ vs. $7.2 \pm 1.8 \mu\text{M}$ in the sham-tolerized group). The anti-
TACHR antibody concentration of individual sham-tolerized mice correlated loosely
15 with the presence of EMG symptoms, that is, mice with EMG symptoms were
among those with the highest antibody concentrations (black symbols in Figure 4).

Nasal Administration of Synthetic DTX Peptides Does Not Affect the Anti-
AChR T and Antibody Responses, or Development of EMG. To test the specificity
of the effects observed after nasal administration of TACHR epitope peptides, the
20 effects on the anti-TACHR response and appearance of EMG after nasal
administration of three DTX peptides were tested. The DTX peptides are highly
immunogenic for human CD4+ cells (Raju et al., 1995), and were of the same length
and synthesized by the same procedure as the TACHR epitope sequences. The
peptides were administered following protocol B. At the same time, two other
25 groups of mice were sham-tolerized with PBS or tolerized with the α pool. None of
the α -pool treated mice developed EMG, while the DTX peptide- and PBS-treated
mice developed EMG with similar frequency (approximately 40%) (Figure 5A).
Mice treated nasally with DTX peptide or PBS developed similar serum anti-AChR
antibody concentrations, which were higher than those of the AChR peptide-

tolerized mice. After the third TACHR immunization, the spleen T cells of 4 mice from each group were pooled and tested for the proliferative response *in vitro* to TACHR. The spleen T cells from DTX peptide treated mice responded well to TACHR, while the responses of spleen T cells of the α pool treated mice were consistently very low (Figure 5B).

The Reduction of the *in vitro* Response to TACHR of Spleen T Cells from AChR Peptide-Tolerized Mice Is Reversed by IL-2. Anergy of antigen specific CD4⁺ T cells is a possible mechanism of T cell tolerization. A test for T cell anergy is a reversal of the nonresponsiveness *in vitro* to the antigen, by treatment of the T cells *in vitro* with IL-2 prior to antigen testing (DeSilva et al., 1991). Two groups of 4 mice each were treated nasally with PBS or with the α pool following protocol B. After the third TACHR injection, the spleen T cells of the mice of each group were pooled, cultured with or without IL-2 as described above, and tested in a proliferation assay for their response to TACHR. Figure 6 depicts the average of the responses of sextuplets of identical cultures, obtained with the different T cells populations.

In the absence of IL-2 treatment, the spleen cells from α pool-tolerized mice responded to TACHR minimally, while those from sham-tolerized mice had a clear response. The IL-2 treatment did not affect the T cell response to TACHR of the sham-tolerized mice, while it increased substantially that of the α pool-tolerized mice.

Nasal Treatment with AChR Peptides Stimulates AChR Specific Th2 Cells. Stimulation of modulatory Th2 cells is another possible mechanism of peripheral tolerance. To test this possibility, the secretion of IL-2 and IL-10 by spleen T cells in response to challenge with TACHR was determined. IL-2 and IL-10 are representative cytokines for Th1 and Th2 subsets, respectively. The same mice treated nasally with PBS or with α pool following protocol B were used for the IL-2 treatment experiments. After the third TACHR injection, the spleen T cells of 4 mice of each group were pooled and tested at different time intervals after addition

of the TACHR for IL-2 and IL-10 secretion in the culture supernatant. The amount of IL-2 in the media was maximal 24 hours after AChR addition. IL-10 was maximal at 48 hours after AChR exposure. The average (n=6) of the data obtained at 24 hours for IL-2 and 48 hours for IL-10 are shown in Figure 7. The presence of TACHR induced the same modest but significant increase of IL-2 secretion in the α pool and sham-tolerized groups. The presence of TACHR did not increase the IL-10 secretion by the T cells from the sham-tolerized mice, while it caused a large increase in the α pool-tolerized group.

- Reduced *in vitro* Response to the TACHR in α pool-tolerized Mice Is Not Due to the Presence in the Culture of Peptide Specific Immunoregulatory Th2 Cells.
- The reduced anti-AChR responses *in vitro* of the spleen T cells from TACHR peptide-tolerized mice could be due to immunoregulatory cytokines secreted in the culture medium by Th2 cells sensitized to the peptide(s) administered nasally. The addition to T cell cultures of the tolerizing peptide together with the TACHR may cause a lesser proliferative response than that to the TACHR alone, because of peptide stimulated cytokine secretion by Th2 cells. As spleen T cells from α pool-tolerized mice had small and erratic proliferative responses to TACHR (see Figures 1, 3, and 5B), these cells could not be used. Thus, spleen T cells from mice treated with DTX peptides and immunized three times with TACHR were used. These T cells had a good proliferative response *in vitro* to TACHR, and a significant proliferative response to the DTX peptides, consistent with T cell sensitization resulting from nasal exposure to the DTX sequences (Figure 8). When DTX peptide was used simultaneously with TACHR, the response obtained was significantly larger than that observed for each of two individual stimulants (Figure 8), and corresponded reasonably well to the sum of the individual responses against TACHR and DTX peptides.

Discussion

Nasal administration of a 20 residue TACHR synthetic peptide, T α 150-169, that forms an immunodominant epitope recognized by pathogenic CD4⁺ cells, effectively protected B6 mice from induction of EMG caused by immunization with TACHR. The treatment was effective when administered prior to and during immunization with TACHR. Moreover, monthly or weekly administrations had comparable effects. This suggests that nasal administration did not cause further priming of pathogenic anti-AChR CD4⁺ T cells. Protection from EMG was associated with reduced T cell reactivity *in vitro* to the TACHR, reduced levels of anti-TACHR antibody in the blood, and minimal or absent proliferative response of spleen T cells to the immunodominant peptide T α 150-169. These effects were antigen-specific, since they could not be reproduced by nasal administration of a control peptide (a DTX peptide).

Although nasal administration of peptides T α 181-200 and T α 360-378 affected subsequent sensitization of T cells to all those sequences (Figure 1), the protective effects on EMG induction are likely due to tolerization of CD4⁺ cells that recognize epitopes within the sequence T α 150-169, because nasal administration of peptide T α 150-169 alone was as effective as administration of the α pool in protecting from EMG and reducing the T and B cell responses to TACHR.

Since the AChR destruction and dysfunction that results in EMG symptoms is caused by antibody binding, it is likely that the altered anti-TACHR CD4⁺ reactivity after nasal tolerization results in protection from EMG because of a change in the anti-AChR antibody repertoire, due to preferential cooperation of different pairs of CD4⁺ helper T cells and B cells (Palmer et al., 1989; Myers, 1991; Bellone et al., 1994). To support this possibility, mice tolerized with TACHR peptides, while protected from EMG, developed substantial amounts of anti-AChR antibodies, but significantly lower than those observed for the mice sham-tolerized with peptide-free PBS (Figure 4), or treated with DTX peptides. The pathogenic antibodies missing in the TACHR peptide-tolerized mice are likely synthesized with

the help of CD4⁺ cells recognizing epitopes within the sequence Tα150-169. An important pathogenic role in mouse EMG of CD4⁺ cells recognizing epitopes within the sequence is supported by several findings: neonatal tolerization to this sequence region reduces susceptibility to EMG (Shenoy et al., 1993); B6 mice primed with AChR and boosted with a synthetic sequence α146-162 developed EMG while mice boosted with a control peptide did not (Shenoy et al., 1994); and in congenic B6 strains carrying the bml2 mutation of the I-A molecule, the ability by CD4⁺ cells to recognize this sequence correlates with propensity to EMG (Karachunski et al., 1995; Bellone et al., 1991; Infante et al., 1991). That CD4⁺ cells sensitized to a single dominant AChR epitope may drive the synthesis of pathogenic anti-AChR antibodies has been shown by transfer experiments for both rat (Yeh et al., 1990) and human (Conti-Fine et al., 1997) CD4⁺ lines against defined AChR epitopes.

Several mechanisms are involved in oral tolerance, including: anergy or deletion by apoptosis of antigen specific T cells, and induction of antigen specific regulatory CD4⁺ Th2 cells (Weiner et al., 1994; Chen et al., 1995). In EAE, it has been shown that the same CD4⁺ precursors can develop into regulatory Th2 cell if the antigen is administered orally, or into encephalitogenic Th1 cells if the antigen is administered subcutaneously in adjuvants (Chen et al., 1996). Antigen-specific regulatory CD4⁺ cells may exert a non-specific down regulating activity through secretion of cytokine, such as IL-4, IL-10, and TGF-β, that act on Th1 cells in topographic proximity, irrespective of their antigen specificity (antigen driven bystander suppression; Weiner et al., 1994).

Oral administration of an antigen can induce tolerance by different mechanisms, depending upon the dose of antigen that was fed (Friedman et al., 1994; Gregerson et al., 1993). Low doses of antigen generate Th2 regulatory cells, whereas high doses induce anergy (Friedman et al., 1994; Gregerson et al., 1993) and/or apoptosis of antigen-reactive Th1 and Th2 cells (Chen et al., 1995). Given the functional similarity of the lymphoid tissues associated with the respiratory and

the gastrointestinal systems, similar mechanisms are likely involved in nasal tolerance (Kuper et al., 1992; Neutra et al., 1994).

Both clonal anergy and sensitization of regulatory Th2 cells seem to have occurred (Figures 6 and 7). High dose clonal deletion by apoptosis is less likely, since the highest doses used were as effective as the lowest (50 μ g, i.e., 20 μ moles). This dose compares in weight to those used for low dose oral tolerance (Friedman et al., 1994). However, the molar concentrations employed in Friedman et al. were lower, as the antigen used in those studies had a higher molecular weight than the peptides employed herein. Epitope-specific anergy induction by nasal treatment with the TACHR peptides is directly supported by the finding that the reduced responsiveness *in vitro* of T cells to TACHR could be reversed by treatment with IL-2 (Figure 6). Further circumstantial evidence for anergy of anti-T α 150-169 T cells is the finding that the proliferative response to the TACHR of the spleen T cells of mice tolerized to DTX epitopes and immunized to TACHR was not reduced by simultaneous stimulation of the T cells sensitized to the DTX peptides: the reduced proliferative response *in vitro* to T α 150-169 and to TACHR is unlikely due to the effects of cytokines released in the culture by Th2 cells.

Anergy or deletion of the T cells recognizing epitopes within the sequence T α 150-169 might suffice to protect from EMG, because, as discussed above, in B6 mice, the CD4⁺ cells that recognize epitopes within this sequence region are uniquely pathogenic. Also, the CD4⁺ response of B6 mice, which were hyperimmunized with TACHR and had a high frequency of EMG, focuses almost exclusively on the sequence T α 150-169, rather than spreading to other TACHR epitopes (Bellone et al., 1993). Thus, sensitization of CD4⁺ cells to epitopes within this sequence suffices to, and is prominent for, driving a pathogenic anti-TACHR antibodies response. This is different from EAE, where progression of the disease correlates with spreading of the CD4⁺ response to new epitopes within MBP and other myelin components (McRae et al., 1995).

Nasal administration of TACHR peptides sensitized AChR-specific Th2 cells, which were not detectable after TACHR immunization in mice sham-tolerized or tolerized to DTX peptides (Figure 7). On the other hand, TACHR immunization *per se* appeared to sensitize Th1 cells only (Figure 7). In MG, Th1 cells are likely involved in the pathogenic anti-AChR response. In EAE, Th1 cells are the direct effectors of demyelination, and their anergy or down regulation by Th2 subset directly affects their pathogenic action, and has therapeutic effects (Chen et al., 1994). On the other hand, in EMG, the protective effects of nasal administration of TACHR are indirect, and the procedures described herein will not have a therapeutic effect when the tolerogenic peptides are administered only after establishment of the pathogenic anti-TACHR antibody response. This is due to the long antibody life and the long life span of activated B cells (Gray, 1993) relative to the time frame of the experiments described herein.

The use of T cell epitope peptides instead of the whole antigen avoids the risk that the nasally administered antigen will prime synthesis of pathogenic antibodies. Even if nasal administration of peptides causes production of anti-peptide antibodies, they are extremely unlikely to cross-react with the cognate native antigen (Conti-Fine et al., 1996). Several studies have shown that (Conti-Fine et al., 1997) immunization with short TACHR peptides does not result in appearance of EMG. Moreover, short synthetic peptides are easily made.

Nasal tolerization using the approach described herein requires knowledge of the autoantigen sequences forming CD4+ epitopes. The CD4+ cells of most MG patients recognize a limited number of epitope sequences of the human AChR (Conti-Fine et al., 1997). Those sequence regions are recognized with high precursor frequency, and should therefore be considered both immunodominant and universal CD4+ epitopes. These epitopes are ideal candidates for application to human MG. The presence on a protein antigen of a few immunodominant, universal epitope sequences for sensitization of human CD4+ cells occurs also for the normal

responses to exogenous antigen, like tetanus and diphtheria toxoid (Raju et al., 1995; Panina-Bordignon et al., 1989; Ho et al., 1990; Diethelm-Okita et al., 1997).

Although the procedure described here affects the anti-AChR antibody secreting B cells indirectly, and it does not have immediate therapeutic effects on established EMG, it also may be a viable candidate for MG management, if associated to plasmapheresis and azathioprine, which eliminate the existing anti-AChR antibodies and affect the activated B cells. The combined effects of such “two pronged” approach might result in a long lasting down regulation of the anti-AChR response, in both the CD4+ and the B cell compartments.

10

Example II

Treatment of Factor VIII-Specific Disease

Approximately 25% of patients with severe hemophilia A develop blocking antibodies (inhibitors) to the missing coagulation factor, factor VIII (FVIII).

15 Inhibitors block FVIII activity, and significantly compromise the ability to achieve therapeutic homeostasis during bleeding episodes. FVIII inhibitors also develop also during autoimmune hemophilia A, a rare but frequently fatal disease in which FVIII is the target of autoimmune response. FVIII inhibitors are high affinity IgG. Their synthesis requires the action of CD4+ T helper cells specific for FVIII.

20 A panel of about 240 synthetic peptides, 20 residues long and overlapping by 10 residues, spanning the FVIII sequence, is screened on T cells to determine which peptides have universal and/or immunodominant epitope sequences. The T cells are obtained from hemophilia A patients, autoimmune hemophilia patients, and healthy individuals that have a CD4+ response to FVIII. Identification of the CD4+ epitope repertoire on FVIII recognized by the patients or healthy individuals can be
25 accomplished by using at least one of three sets of complimentary experiments, as follows: 1) Identification of the epitope repertoire of unselected CD4+ cells from the patient's blood by proliferation experiments using CD8+ depleted, CD4+ enriched peripheral blood lymphocytes (PBL), challenged with each individual peptide. 2)

Identification of the CD4⁺ subset (Th1 or Th2) recognizing the different FVIII epitopes, by immunospot assays of the cytokines secreted by individual blood CD4⁺ cells in response to challenge with the different FVIII peptides. Preferably, IL-2 and γ -interferon are employed to detect Th1 cells, and IL-4 is employed to detect Th2 cells. 3) Propagation of FVIII-specific CD4⁺ lines, by cycles of stimulation *in vitro* of the PBL with FVIII followed by IL-2 or IL-4, and determination of their epitope repertoire and the Th1 or Th2 subset involved in the anti-epitope response, by challenging them with individual synthetic sequences in proliferation and immunospot assays.

10 To identify the CD4⁺ epitope repertoire on FVIII in the hemophilia A mice (Bi et al., Nature Genet., 10, 119 (1995)), CD8⁺ depleted, CD4⁺ enriched spleen cells are employed instead of PBL. The mice have been injected with FVIII i.v. three times prior to spleen cell isolation, or by other routes that result in an immune response to FVIII. Alternatively, CD4⁺ cells are purified from the spleen and reconstituted with autologous antigen presenting cells. Peptides are screened by assays described herein to identify universal and/or immunodominant epitopes of FVIII. The C1 and the C2 domains of FVIII appeared to dominate the CD4⁺ response to FVIII of the mice. Once peptides having a universal and/or immunodominant epitope sequences are identified, they are administered nasally to hemophilia A mice prior to and during immunization with FVIII. Control mice are sham tolerized with peptide-free PBS. The effects of the tolerization on the antibody and CD4⁺ response to FVIII of the nasal administration of peptides is then determined.

Healthy humans have recurrent, transient sensitization of CD4⁺ cells to FVIII. This is likely due to extravasation of FVIII at sites, such as bruises, where FVIII sequence may be presented by professional antigen presenting cells, able to prime potentially autoreactive CD4⁺ cells specific for FVIII epitopes. In normal individuals, who have high blood levels of FVIII, the activated anti-FVIII CD4⁺ cells quickly disappear, possibly as a result of anergy or deletion by peripheral

mechanisms of tolerance. Such cells persist in hemophilia A patients because their low FVIII levels, even after therapy, do not suffice for tolerization. Thus, the presence of anti-FVIII CD4⁺ cells in healthy humans can assist in the identification of universal CD4⁺ epitopes for FVIII.

5 A panel of overlapping peptides for FVIII were prepared which were 20 residues long, a length that compares with that of naturally processed class II restricted epitopes are peptides that are 9-14 residues long, and which overlapped by 10 residues. Thus, extra residues at either end of the peptide should not affect the peptide attachment to the binding cleft of the DR molecules, which is open at both
10 ends. Moreover, the use of peptides of a length within the range of naturally processed peptides may result in the presentation of the specific epitope(s) without the need for processing, and may avoid the failure to stimulate the epitope-specific T cell to inappropriate peptide processing.

 The CD4⁺ cells from twelve healthy subjects were screened with a pool of
15 FVIII peptides, e.g, 24 pools of 10 peptides each (Figure 11). All subjects recognized one or more peptide pools. The pools comprising the sequence of the A2, A3 and C2 domains were recognized most strongly and most frequently. Anti-FVIII antibodies, including the inhibitors in hemophilia patients recognize primarily (but not exclusively) epitopes formed by the A2 and C2 domains. Thus, it appears
20 that those domains may dominate both the pathogenic immune response to FVIII that leads to inhibitor formation in hemophilia A and the ephemeral, nonpathogenic responses of healthy subjects. Some subjects did not have a detectable response to the complete FVIII molecule, in spite of their significant response to one or more peptide pools. This is likely due to the much higher concentration of epitope
25 sequences in the assays carried out with the peptides, than in those testing the response to FVIII.

References

- Abbas, A.K., K.M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. *Nature* 383:787-793.
- Al-Sabbagh, A., P. Nelson, Y. Akselband, R. Sobel, and H. Weiner. 1996.
- 5 Antigen driven peripheral immune tolerance - suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen. *Cell Immunol.* 171:111-119.
- Akamizu, T., F. Matsuda, J. Okuda, H. Li, B. Kanda, T. Watanabe, T. Honjo
- 10 and T. Mori. 1996. Molecular analysis of stimulatory anti-thyrotropin receptor antibodies (TSAbs) involved in Graves' disease. *J. Immunol.* 157 :3148-3152.
- Bellone, M., N. Ostlie, S. Lei, X-D. Wu, and B. Conti-Tronconi. 1991. The I-A bm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic
- 15 acetylcholine receptor. *J. Immunol.* 147:1484-1491.
- Bellone, M., N. Ostlie, S. Lei, and B. Conti-Tronconi. 1991. Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the α subunits of *Torpedo californica* and murine acetylcholine receptors. *Eur. J. Immunol.* 21:2303-2310.
- 20 Bellone, M., N. Ostlie, P. Karachunski, A. Manfredi, and B. Conti-Tronconi. 1993. Cryptic epitopes on the nicotinic acetylcholine receptor are recognized by autoreactive CD4+ cells. *J. Immunol.* 151:1025-1038.
- Bellone, M., P. Karachunski, N. Ostlie, S. Lei, and B. Conti-Tronconi. 1994. Preferential pairing of T and B cells for production of antibodies without covalent
- 25 association of T and B epitopes. *Eur. J. Immunol.* 24:799-804.
- Benjamini et al. (eds.), Immunology: A Short Course, John Wiley & Sons, Inc., 3rd ed. (1996).

Chen, Y., V.K. Kuchroo, J. Inobe, D.A. Hafler, and H.L. Weiner. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. *Science* 265:1237-1240.

- Chen, Y., J. Inobe, R. Marks, P. Gonnella, V. Kuchroo, and H. Weiner.
5 1995. Peripheral deletion of antigen-reactive T cells in oral tolerance. *Nature* 376:177-180.

- Chen, Y., J. Inobe, V. Kuchroo, J. Baron, C.J. Janeway, and H. Weiner.
1996. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of
10 regulatory cells. *Proc. Natl. Acad. Sci. USA* 93:388-391.

Conti-Fine, B.M, K.E. McLane, and S. Lei. 1996. Antibodies as a tool to study the structure of membrane proteins. The case of the nicotinic receptor. *Ann. Rev. Biophys. Biomol. Struct.* 25:197-229.

- Conti-Fine, B.M., M.P. Protti, M. Bellone, and J.F. Howard, Jr. 1997.
15 Myasthenia Gravis: The Immunobiology of an Autoimmune Disease. R.G. Landes Company, Austin. 230pp.

DeSilva, D.R., Urdahl, K.B., and M.K. Jenkins. 1991. Clonal anergy is induced *in vitro* by T cell receptor occupancy in the absence of proliferation. *J. Immunol.* 147:3261-3267.

- 20 Dick, A., Y. Cheng, A. McKinnon, J. Liversidge, and J. Forrester. 1993. Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. A preliminary report of intranasal induction of tolerance with retinal antigens. *Brit. J. Ophthalmol.* 77:171-175.

- Diethelm-Okita, B., R. Raju, D. Okita, and B. Conti-Fine. 1997. Epitope
25 repertoire of human CD4+ T cells on tetanus toxin: identification of immunodominant sequence segments. *J. Infect. Dis.* 175:382-391.

Friedman, A., and H.L. Weiner. 1994. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. *Proc. Natl. Acad. Sci. USA* 91:6688-6692.

- Genain, C.P., K. Abel, N. Belmar, F. Villinger, D.P. Rosenberg, C. Linington, C.S. Raine, and S.L. Hauser. 1996. Late complications of immune deviation therapy in a nonhuman primate. *Science* 274:2054-7.
- Gray, D. 1993. Immunological memory. *Ann. Rev. Immunol.* 11:49-77.
- 5 Gregerson, D., W. Obritsch, and L. Donoso. 1993. Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs. high dose feeding protocols. *J. Immunol.* 151:5751-5761.
- Hashimoto, T. 1993. Cadherins and blistering skin diseases. *Curr. Opin. Dermatol.* 2, 244-249.
- 10 Ho, P., D. Mutch, K. Winkel, A.J. Saul, G.L. Jones, T.J. Doran, and C.M. Rzepczyk. 1990. Identification of two promiscuous T cell epitopes from tetanus toxin. *Eur. Immunol.* 20:477-483.
- Houghten, R. 1985. General method for the rapid solid phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. *Proc. Natl. Acad. Sci. USA* 82:5131-5135.
- 15 Husby, S., J. Mestecky, Z. Moldoveanu, S. Holland, and C. Elson. 1994. Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. *Immunol.* 152:4663-4670.
- Infante, A., P. Thompson, K. Krolik, and K. Wall. 1991. Determinant selection in murine experimental autoimmune myasthenia gravis: Effect of the bm12 mutation on T-cell recognition of acetylcholine receptor epitopes. *J. Immunol.* 146:2977-2982.
- 20 Karachunski, P., N. Ostlie, M. Bellone, A. Infante, and B. Conti-Fine. 1995. Mechanisms by which the I-A bm12 mutation influences susceptibility to experimental myasthenia gravis: a study in homozygous and heterozygous mice. *Scand. J. Immunol.* 42:215-225.
- 25 Karpus, W. J., K.J. Kennedy, W.S. Smith, and S. D. Miller. 1996. Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP 139-151 peptide. *Neuroscience Research* 45:410-423.

Kellerman, S. D. McCormick, S. Freeman, John C. Morris and B.M. Conti-Fine. 1995. TSH receptor sequences recognized by CD4+ cells in Graves' disease patients and in healthy controls. *J.Autoimmunity* 8:685-698, 1995.

Kuper, C., P. Koornstra, D. Hameleers, J. Biewenga, B.J. Spit, A.M.

- 5 Duijvestijn, P.J. van Breda Vriesman, and T. Sminia. 1992. The role of nasopharyngeal lymphoid tissue. *Immunol. Today* 13:219-224.

Laemmli, U. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680.

- Liu, L., and G.G. MacPherson. 1993. Antigen acquisition by dendritic cells: intestinal dendritic cells acquire antigen administered orally and can prime naive T cells *in vivo*. *J. Exp. Med.* 177:1299-1307.

Lowry, O., N. Rosebrough, A. Farr, and R. Randall. 1981. Protein measurement with Folin phenol reagent. *J. Biol. Chem.* 193:256.

Ma, C., G. Zhang, B. Xiao, J. Link, T. Olsson, and H. Link. 1995.

- 15 Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. *J. Neuroimmunol.* 58:51-60.

Manfredi, A. M.H. Yuen, L. Moiola, M.P. Protti and B.M. Conti-Tronconi. 1994. Human acetylcholine receptor presentation in Myasthenia Gravis: DR restriction of autoimmune T epitopes and binding of synthetic receptor sequences to DR molecules. *J. Immunol.* 152: 4165-4174.

- 20 Matzinger, P. 1994. Tolerance, danger, and the extended family. *Ann. Rev. Immunol.* 12:991-1045.

McRae, B., C. Vanderlugt, M. Dal Canto, and S. Miller. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. *J. Exp. Med.* 182:75-85.

Memar, B. Christensen, S. Raiararnan, R. Goldblum, .K. Tying, M,M. Brysk, D.J. McCormick, H. El Zaim, J-L. Pan and B.S. Prabhakar. 1996. Induction of blister-causing antibodies by a recombinant full-length, but not the extracellular,

domain of the pemphigus vulgaris antigen (Desmoglein 3). *J. Immunol.* 157: 3171-3177.

- Metzler, B., and D.C. Wraith. 1993. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. *Int. Immunol.* 5:1159-1169.

Miller, A., O. Lider, O. Abramsky, and H.L. Weiner. 1994. Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. *Eur. J. Immunol.* 24:1026-32.

- Myers C. 1991. Role of B cell antigen processing and presentation in the humoral immune response. *FASEB* 5:2547.

Neutra, M., E. Pringult, and J. Kraehenbuhl. 1996. Antigen sampling across epithelial barriers and induction of mucosal immune response. *Ann. Rev. Immunol.* 14:275-300.

- Nossal, G. 1995. Choices following antigen entry: antibody formation or immunologic tolerance? *Ann. Rev. Immunol.* 13:1-27.

- Palmer, M, and Sercarz, E. 1989. Determinant preferences in the relationship between T and B cell specific for lysozyme. In: *The Immune Response to Structurally Defined Proteins: The Lysozyme Model*. S. Smith-Gill, E. Sercarz, editors. New York:Academic Press, pp. 285-321.

Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. *Eur. J. Immunol.* 19:2237-2242.

- Paul, Fundamental Immunology, 3rd ed., Raven Press (1993).

Plott, R.T. , M. Amagai, M.C. Udey and J.R. Stanley. 1994. Pemphigus vulgaris antigen lacks biochemical properties characteristic of classical cadherins. *J. Invest. Dermatol.* 17:168-172.

Raju R., D. Navaneetham, D. Okita, B. Diethelm-Okita, D. McCormick, and B. Conti-Fine. 1995. Epitopes for human CD4+ cells on diphtheria-toxin: structural features of sequence segments forming epitopes recognized by most subjects. *Eur. J. Immunol.* 25:3207-3214.

- 5 Raju, R., B. Diethelm-Okita, B., D.K. Okita, and B. M. Conti-Fine. 1996. Epitope repertoire of human CD4+ lines propagated with tetanus toxoid or synthetic tetanus sequences. *J. Autoimmunity* 9:79-88.

Schmidt, J., and M. Raftery. 1973. A simple assay for the study of solubilized acetylcholine receptors. *Anal. Biochem.* 52:349-354.

- 10 Shenoy, M., M. Oshima, M. Atassi, and P. Christadoss. 1993. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor. *Clin. Immunol. Immunopathol.* 66:230-238.

- 15 Shenoy, M., E. Goluszko, and P. Christadoss. 1994. The pathogenic role of acetylcholine receptor α chain epitope within α 146-162 in the development of experimental autoimmune myasthenia gravis in C57Bl/6 mice. *Clin. Immunol. Immunopathol.* 73:1-6.

Stanley, J.R. 1995. Autoantibodies against Adhesion Molecules and Structures in Blistering Skin diseases. *J. Experimental Medicine* 181:1-4.

- 20 Texier, B., C. Bedin, H. Taiig, L. Camoin, C. Laurent-Winter and J. Charreire. 1992. Characterization and sequencing of a 40-amino-acid peptide from human thyroglobulin inducing experimental autoimmune thyroiditis. *J. Immunol.* 148: 3405-3411.

- 25 Wang, Z-Y., D. Okita, J. Howard Jr., and B. Conti-Fine. 1997. Th1 epitope repertoire on the alpha subunit of human muscle acetylcholine receptor in Myasthenia Gravis. *Neurology* 48:1643-1653.

Weetman, A. P. and A.M. McGregor. 1994. Autoimmune thyroid disease, Further developments in our understanding. *Endocrin. Rev.* 15: 788-830.

Weiner, H., A. Friedman, A. Miller, S.J. Khoury, A. Al-Sabbagh, L. Santos, M. Sayegh, R.B. Nussenblatt, D.E. Trentham, and A.D. Hafler. 1994. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. *Ann. Rev. Immunol.* 12:809-837.

Yeh, T.M., and K.A. Krolick. 1990. T cells reactive with a small synthetic peptide of the acetylcholine receptor can provide help for a clonotypically heterogeneous antibody response and subsequently impaired muscle function. *J. Immunol.* 144:1654-1660.

10 Yu, M., J. Johnson, and V. Tuohy. 1996. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. *J. Exp. Med.* 183:1777-1788.

Yuen, M.H., K. Macklin and Bianca M. Conti-Fine. 1996.
15 MHC class II presentation of human acetylcholine receptor in Myasthenia Gravis. Binding of synthetic gamma subunit sequences to purified DR molecules. *J. Autoimmunity*, 9:67-77.

All publications, patents and patent applications are incorporated herein by
20 reference. While in the foregoing specification this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic
25 principles of the invention.

WHAT IS CLAIMED IS:

1. A method of preventing or inhibiting an indication or disease associated with aberrant, pathogenic or undesirable antibody production which is specific for a particular antigen, comprising: administering to a mammal afflicted with, or at risk of, the indication or disease a dosage form comprising an amount of at least one epitope peptide, a variant thereof or a combination thereof, effective to prevent or inhibit at least one symptom of said indication or disease, wherein the sequence of the epitope peptide comprises an immunodominant epitope sequence and wherein the peptide comprises less than the sequence of the antigen, and wherein the antigen comprises said immunodominant epitope sequence.

2. A method of preventing or inhibiting an indication or disease associated with aberrant, pathogenic or undesirable antibody production which is specific for a particular antigen, comprising: administering to a mammal afflicted with, or at risk of, the indication or disease a dosage form comprising an amount of at least one epitope peptide, a variant thereof or a combination thereof, effective to suppress, tolerize or inhibit the priming or activity of, T cells of said mammal, wherein the T cells are specific for the antigen, wherein the sequence of the epitope peptide comprises an immunodominant epitope sequence, wherein the peptide comprises less than the sequence of the antigen, and wherein the antigen comprises the immunodominant epitope sequence.

3. The method of claim 1 wherein the administration is effective to reduce or inhibit the amount of said antibody or the affinity of said antibody for an antigen comprising said peptide.

4. The method of claim 1 or 3 wherein the antigen is an endogenous antigen.

5. The method of claim 4 wherein the endogenous antigen is the acetylcholine receptor, insulin, growth hormone, factor VIII or factor IX
6. The method of claim 1 or 3 wherein the antigen is an exogenous antigen.
7. The method of claim 6 wherein the exogenous antigen is a fungal antigen.
8. The method of claim 2 wherein the administration is effective to reduce or inhibit the amount of said antibody or the affinity of said antibody for an antigen comprising said peptide.
9. The method of claim 2 or 8 wherein the antigen is an exogenous antigen.
10. The method of claim 9 wherein the exogenous antigen is a fungal antigen.
11. The method of claim 2 or 8 wherein the antigen is an endogenous antigen.
12. The method of claim 11 wherein the endogenous antigen is the acetylcholine receptor, insulin, growth hormone, factor VIII or factor IX.
13. The method of claim 1 or 2 wherein the mammal is a human.
14. The method of claim 13 wherein the peptide comprises a universal, immunodominant epitope sequence.
15. The method of claim 1 or 2 wherein the dosage form is administered to the respiratory tract.

16. The method of claim 15 wherein the antigen is an exogenous antigen from a domestic cat.

17. A method to tolerize a mammal to an antigen associated with aberrant, pathogenic or undesirable antibody production in the mammal, comprising: administering at least one epitope peptide, a variant thereof or a combination thereof, having a universal immunodominant epitope sequence to the mammal in an amount effective to tolerize the mammal to an antigen having said epitope, wherein the sequence of the epitope peptide comprises an immunodominant epitope sequence and wherein the peptide comprises less than the sequence of the antigen.

18. The method of claim 17 wherein the peptide is nasally administered.

19. A method to identify an immunodominant epitope sequence useful to tolerize a mammal, comprising:

- (a) contacting a plurality of samples with a plurality of peptides, wherein the samples to be tested comprise T cells of a mammal, wherein each sample is contacted with a different peptide, and wherein the mammal is sensitized to an antigen comprising said peptide; and
- (b) detecting or determining whether the T cells of the mammal in one sample proliferate relative to other samples and relative to T cells which were not exposed to a peptide.

20. A method to identify an immunodominant epitope sequence useful to tolerize a mammal, comprising:

- (a) contacting a plurality of samples with a plurality of peptides, wherein the samples to be tested comprise T cells of a mammal, wherein each sample is contacted with a different peptide, and wherein the mammal is sensitized to an antigen comprising said peptide; and

(b) detecting or determining whether the T cells of the mammal in one sample proliferate relative to other samples and relative to T cells which were exposed to a peptide that does not comprise an immunodominant epitope peptide.

21. A method to identify a universal epitope sequence in a mammal, comprising:

(a) contacting at least two samples obtained from at least two mammals with a preselected peptide, wherein one sample comprises CD4⁺ cells obtained from a first individual mammal, wherein the second sample comprises CD4⁺ cells obtained from a second individual mammal, wherein the genotype of the second mammal at the immune response loci differs from the genotype of the first mammal, and wherein the mammals are of the same species; and
(b) detecting or determining whether the CD4⁺ cells of each mammal proliferate relative to CD4⁺ cells which were not contacted with the peptide.

22. A therapeutic method, comprising: administering to the respiratory tract of a mammal subjected to gene therapy which employs a recombinant virus as a delivery vehicle, an amount of an epitope peptide, a variant thereof or a combination thereof effective to suppress an immune response to the virus-specific proteins present in the delivery vehicle, wherein the epitope peptide comprises an immunodominant epitope sequence of the virus protein.

23. A therapeutic method, comprising: administering to the respiratory tract of a mammal having an indication or disease characterized by a decreased amount or a lack of an endogenous protein and which mammal is subjected to exogenous introduction of the endogenous protein or the corresponding recombinant polypeptide, an amount of an epitope peptide, a variant thereof or a combination thereof effective to suppress an immune response to the exogenously

introduced protein or polypeptide, wherein the indication or disease is associated with aberrant or pathogenic antibody production to the endogenous protein, and wherein the sequence of the epitope peptide comprises an immunodominant epitope sequence and wherein the peptide comprises less than the sequence of the endogenous protein which comprises the immunodominant epitope sequence.

24. A therapeutic method, comprising: administering to the respiratory tract of a mammal subjected to gene therapy which employs a recombinant virus as a delivery vehicle and which recombinant virus encodes an endogenous protein which said mammal is in need of, an amount of an epitope peptide, a variant thereof or a combination thereof effective to suppress an immune response to the encoded protein, wherein the peptide comprises an immunodominant epitope sequence of the endogenous protein, and wherein the sequence of the epitope peptide comprises less than the sequence of the endogenous protein.

25. The method of claim 23 or 24 wherein the disease is hemophilia or diabetes.

26. The method of claim 23 wherein the indication is adenosine deamidase deficiency, growth hormone deficiency, insulin deficiency, factor IX deficiency or factor VIII deficiency.

27. The method of claim 22 or 24 wherein the viral vector is a retroviral vector.

28. The method of claim 22 or 24 wherein the viral vector is an adenoviral vector.

29. A tolerogen comprising at least one isolated and purified peptide having an immunodominant epitope sequence, the administration of which to a sensitized mammal results in the suppression of the immune response of that mammal to an antigen which comprises at least an immunogenic portion of the peptide.

30. The tolerogen of claim 29 wherein the dosage form is adaptable for administration to the respiratory tract.

31. The method claim 1, 2, 17, 22, 23 or 24 wherein the administration does not increase synthesis of pathogenic antibody to the native antigen.

32. A method to inhibit or treat an antibody-mediated disease in a mammal, wherein the disease is characterized by antibodies specific for an antigen comprising:

(a) administering to the mammal a dosage form comprising an amount of at least one epitope peptide, a variant thereof or a combination thereof, effective to prevent or inhibit at least one symptom of said disease, wherein the sequence of the epitope peptide comprises an immunodominant epitope sequence, wherein the antigen comprises said immunodominant epitope sequence, and wherein the peptide comprises less than the sequence of the antigen which comprises said immunodominant epitope sequence; and

(b) subjecting the mammal to plasmapheresis.

33. The method of claim 32 further comprising administering an agent that inhibits B cell activation.

Abstract of the Invention

Isolated and purified peptides and variants thereof, useful to prevent or treat antibody-mediated diseases, or indications caused by an undesirable antibody response to a given antigen, are provided. Also provided are peptides and methods useful to prevent or treat indications associated with the use of viral vectors in gene replacement therapy. Further, a method to inhibit or prevent aberrant immune responses to exogenous, non-infectious antigen is provided.

"Express Mail" mailing label number: EM014196877US
Date of Deposit: December 16, 1997
I hereby certify that this paper or fee is being deposited with the
United States Postal Service "Express Mail Post Office to Addressee"
service under 37 CFR 1.10 on the date indicated above and is
addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231
Name: Patricia A. Dultman
Signature: Patricia A. Dultman




Fig. 1

Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7





Fig. 8

Figure 9

<u>Amino Acid</u>	<u>Codon</u>
Phe	UUU, UUC
Ser	UCU, UCC, UCA, UCG, AGU, AGC
Tyr	UAU, UAC
Cys	UGU, UGC
Leu	UUA, UUG, CUU, CUC, CUA, CUG
Trp	UGG
Pro	CCU, CCC, CCA, CCG
His	CAU, CAC
Arg	CGU, CGC, CGA, CGG, AGA, AGG
Gln	CAA, CAG
Ile	AUU, AUC, AUA
Thr	ACU, ACC, ACA, ACG
Asn	AAU, AAC
Lys	AAA, AAG
Met	AUG
Val	GUU, GUC, GUA, GUG
Ala	GCU, GCC, GCA, GCG
Asp	GAU, GAC
Gly	GGU, GGC, GGA, GGG
Glu	GAA, GAG

Figure 10

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; lys; arg	gln
Asp (D)	glu	glu
Cys (C)	ser	ser
Gln (Q)	asn	asn
Glu (E)	asp	asp
Gly (G)	pro	pro
His (H)	asn; gln; lys; arg	arg
Ile (I)	leu; val; met; ala; phe norleucine	leu
Leu (L)	norleucine; ile; val; met; ala; phe	ile
Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile	leu
Phe (F)	leu; val; ile; ala	leu
Pro (P)	gly	gly
Ser (S)	thr	thr
Thr (T)	ser	ser
Trp (W)	tyr	tyr
Tyr (Y)	trp; phe; thr; ser	phe
Val (V)	ile; leu; met; phe; ala; norleucine	leu



United States Patent Application

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: METHODS TO TREAT UNDESIRABLE IMMUNE RESPONSES.

The specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (see page 3 attached hereto).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on the basis of which priority is claimed:

No such applications have been filed.

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

No such applications have been filed.

I hereby claim the benefit under Title 35, United States Code, § 120/365 of any United States and PCT international application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

No such applications have been filed.

I hereby appoint the following attorney(s) and/or patent agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith:

Anglin, J. Michael
Bianchi, Timothy E.
Billig, Patrick G.
Billion, Richard E.
Brennan, Thomas F.
Brooks, Edward J., III
Clark, Barbara J.
Drake, Eduardo E.
Dryja, Michael A.

Reg. No. 24,916
Reg. No. 39,610
Reg. No. 38,080
Reg. No. 32,836
Reg. No. 35,075
Reg. No. 40,925
Reg. No. 38,107
Reg. No. 40,594
Reg. No. 39,662

Embretson, Janet E.
Fogg, David N.
Forrest, Bradley A.
Harris, Robert J.
Hofmann, Rudolph P., Jr.
Holloway, Sheryl S.
Klima-Silberg, Catherine I.
Kluth, Daniel J.
Lemaire, Charles A.

Reg. No. 39,665
Reg. No. 35,138
Reg. No. 30,837
Reg. No. 37,346
Reg. No. 38,187
Reg. No. 37,850
Reg. No. 40,052
Reg. No. 32,146
Reg. No. 36,198

Litman, Mark A.
Lundberg, Steven W.
Madrid, Andres N.
Schwegman, Micheal L.
Simboli, Paul B.
Slifer, Russell D.
Viksnins, Ann S.
Woessner, Warren D.

Reg. No. 26,390
Reg. No. 30,568
Reg. No. 40,710
Reg. No. 25,816
Reg. No. 38,616
Reg. No. 39,838
Reg. No. 37,748
Reg. No. 30,440

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/organization/who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Schwegman, Lundberg, Woessner & Kluth, P.A. to the contrary.

Please direct all correspondence in this case to Schwegman, Lundberg, Woessner & Kluth, P.A. at the address indicated below:

P.O. Box 2938, Minneapolis, MN 55402
Telephone No. (612)373-6900

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of sole inventor : **Bianca M. Conti-Fine**
Citizenship: **United States of America** Residence: **Minneapolis, MN**
Post Office Address: 2424 Lake Place
Minneapolis, MN 55405

Signature: _____ Date: _____
Bianca M. Conti-Fine

Full Name of inventor:
Citizenship: Residence:
Post Office Address:

Signature: _____ Date: _____

Full Name of inventor:
Citizenship: Residence:
Post Office Address:

Signature: _____ Date: _____

Full Name of inventor:
Citizenship: Residence:
Post Office Address:

Signature: _____ Date: _____

§ 1.56 Duty to disclose information material to patentability.

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
- (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) Each inventor named in the application;
- (2) Each attorney or agent who prepares or prosecutes the application; and
- (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.